Patent Application
20230391763
The present invention relates to compounds of formula (I)
or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R3, R4a, R4b, R4c, R4d, R4f, X1, X2 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising said compounds, their use as medicament and in a method for treating or preventing of one or more diseases or disorders associated with integrated stress response.
The Integrated Stress Response (ISR) is a cellular stress response common to all eukaryotes (1). Dysregulation of ISR signaling has important pathological consequences linked inter alia to inflammation, viral infection, diabetes, cancer and neurodegenerative diseases.
ISR is a common denominator of different types of cellular stresses resulting in phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) on serine 51 leading to the suppression of normal protein synthesis and expression of stress response genes (2). In mammalian cells the phosphorylation is carried out by a family of four eIF2alpha kinases, namely: PKR-like ER kinase (PERK), double-stranded RNA-dependent protein kinase (PKR), heme-regulated eIF2alpha kinase (HRI), and general control non-derepressible 2 (GCN2), each responding to distinct environmental and physiological stresses (3). eIF2alpha together with eIF2beta and eIF2gamma form the eIF2 complex, a key player of the initiation of normal mRNA translation (4). The eIF2 complex binds GTP and Met-tRNAi forming a ternary complex (eIF2-GTP-Met-tRNAi), which is recruited by ribosomes for translation initiation (5, 6).
eIF2B is a heterodecameric complex consisting of 5 subunits (alpha, beta, gamma, delta, epsilon) which in duplicate form a GEF-active decamer (7).
In response to ISR activation, phosphorylated eIF2alpha inhibits the eIF2B-mediated exchange of GDP for GTP, resulting in reduced ternary complex formation and hence in the inhibition of translation of normal mRNAs characterized by ribosomes binding to the 5′ AUG start codon (8). Under these conditions of reduced ternary complex abundance the translation of several specific mRNAs including the mRNA coding for the transcription factor ATF4 is activated via a mechanism involving altered translation of upstream ORFs (uORFs) (7, 9, 10). These mRNAs typically contain one or more uORFs that normally function in unstressed cells to limit the flow of ribosomes to the main coding ORF. For example, during normal conditions, uORFs in the 5′ UTR of ATF occupy the ribosomes and prevent translation of the coding sequence of ATF4. However, during stress conditions, i.e. under conditions of reduced ternary complex formation, the probability for ribosomes to scan past these upstream ORFs and initiate translation at the ATF4 coding ORF is increased. ATF4 and other stress response factors expressed in this way subsequently govern the expression of an array of further stress response genes. The acute phase consists in expression of proteins that aim to restore homeostasis, while the chronic phase leads to expression of pro-apoptotic factors (1, 11, 12, 13).
Upregulation of markers of ISR signaling has been demonstrated in a variety of conditions, among these cancer and neurodegenerative diseases. In cancer, ER stress-regulated translation increases tolerance to hypoxic conditions and promotes tumor growth (14, 15, 16), and deletion of PERK by gene targeting has been shown to slow growth of tumours derived from transformed PERK−/− mouse embryonic fibroblasts (14, 17). Further, a recent report has provided proof of concept using patient derived xenograft modeling in mice for activators of eIF2B to be effective in treating a form of aggressive metastatic prostate cancer (28). Taken together, prevention of cytoprotective ISR signaling may represent an effective anti-proliferation strategy for the treatment of at least some forms of cancer.
Further, modulation of ISR signaling could prove effective in preserving synaptic function and reducing neuronal decline, also in neurodegenerative diseases that are characterized by misfolded proteins and activation of the unfolded protein response (UPR), such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD) and Jakob Creutzfeld (prion) diseases (18, 19, 20). With prion disease an example of a neurodegenerative disease exists where it has been shown that pharmacological as well as genetic inhibition of ISR signaling can normalize protein translation levels, rescue synaptic function and prevent neuronal loss (21). Specifically, reduction of levels of phosphorylated eIF2alpha by overexpression of the phosphatase controlling phosphorylated eIF2alpha levels increased survival of prion-infected mice whereas sustained eIF2alpha phosphorylation decreased survival (22).
Further, direct evidence for the importance of control of protein expression levels for proper brain function exists in the form of rare genetic diseases affecting functions of eIF2 and eIF2B. A mutation in eIF2gamma that disrupts complex integrity of eIF2 and hence results in reduced normal protein expression levels is linked to intellectual disability syndrome (ID) (23). Partial loss of function mutations in subunits of eIF2B have been shown to be causal for the rare leukodystrophy Vanishing White Matter Disease (VWMD) (24, 25). Specifically, stabilization of eIF2B partial loss of function in a VWMD mouse model by a small molecule related to ISRIB has been shown to reduce ISR markers and improve functional as well as pathological end points (26, 27).
Modulators of the eIF2 alpha pathway are described in WO 2014/144952 A2. WO 2017/193030 A1, WO 2017/193034 A1, WO 2017/193041 A1 and WO 2017/193063 A1 describe modulators of the integrated stress pathway. WO 2017/212423 A1, WO 2017/212425 A1, WO 2018/225093 A1, WO 2019/008506 A1 and WO 2019/008507 A1 describe inhibitors of the ATF4 pathway. WO 2019/032743 A1, WO 2019/046779 A1, WO 2020/167994 A1, WO 2020/168011 A1 and WO 2020/181247 A1 relate to eukaryotic initiation factor 2B modulators. In WO 2020/77217 A1 compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions are described.
Further documents describing modulators of the integrated stress pathway are WO 2019/090069 A1, WO 2019/090074 A1, WO 2019/090076 A1, WO 2019/090078 A1, WO 2019/090081 A1, WO 2019/090082 A1, WO 2019/090085 A1, WO 2019/090088 A1, WO 2019/090090 A1, WO 2020/223536 A1, WO 2020/223538 A1, WO 2020/252207 A1, European patent applications 20203309.8 and 20203312.2, WO 2021/180774 A1, WO 2021/151865 A1, WO 2020/216764 A1 and WO 2020/216766 A1.
Modulators of eukaryotic initiation factors are described in WO 2019/183589 A1. WO 2019/118785 A2, WO 2019/236710 A1, WO 2020/176428 A1 and WO 2020/252205 A1 describe inhibitors of the integrated stress response pathway. Heteroaryl derivatives as ATF4 inhibitors are described in WO 2019/193540 A1. Bicyclic aromatic ring derivatives as ATF4 inhibitors are described in WO 2019/193541 A1. WO 2020/031107 A1 and WO 2020/012339 A1 describe inhibitors of the ATF4 pathway.
However, there is a continuing need for new compounds useful as modulators of the integrated stress response pathway with good pharmacokinetic properties.
Thus, an object of the present invention is to provide a new class of compounds as modulators of the integrated stress response pathway, which may be effective in the treatment of integrated stress response pathway related diseases and which may show improved pharmaceutically relevant properties including activity, solubility, selectivity, ADMET properties and/or reduced side effects.
Accordingly, the present invention provides a compound of formula (I)
Surprisingly, the disclosed example compounds according to the present invention have favourable physico-chemical properties and/or selectivity, which combine to help to achieve beneficial therapeutic efficacy whilst limiting unintended liabilities.
In case a variable or substituent can be selected from a group of different variants and such variable or substituent occurs more than once the respective variants can be the same or different.
Within the meaning of the present invention the terms are used as follows:
The term “optionally substituted” means unsubstituted or substituted. Generally—but not limited to—, “one or more substituents” means one, two or three, preferably one or two substituents and more preferably one substituent. Generally these substituents can be the same or different. The term “one or more substituents” also means by way of example one, two, three, four or five, preferably by way of example one, two, three or four.
“Alkyl” means a straight-chain or branched hydrocarbon chain. Each hydrogen of an alkyl carbon may be replaced by a substituent as further specified.
“Alkenyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon double bond. Each hydrogen of an alkenyl carbon may be replaced by a substituent as further specified.
“Alkynyl” means a straight-chain or branched hydrocarbon chain that contains at least one carbon-carbon triple bond. Each hydrogen of an alkynyl carbon may be replaced by a substituent as further specified.
“C1-4 alkyl” means an alkyl chain having 1-4 carbon atoms, e.g. if present at the end of a molecule: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or e.g. —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(C2H5)—, —C(CH3)2—, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C1-4 alkyl carbon may be replaced by a substituent as further specified. The term “C1-3 alkyl” is defined accordingly.
“C1-6 alkyl” means an alkyl chain having 1-6 carbon atoms, e.g. if present at the end of a molecule: C1-4 alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, or e.g. —CH2—, —CH2—CH2—, —CH(CH3)—, —CH2—CH2—CH2—, —CH(C2H5)—, —C(CH3)2—, when two moieties of a molecule are linked by the alkyl group. Each hydrogen of a C1-6 alkyl carbon may be replaced by a substituent as further specified.
“C2-6 alkenyl” means an alkenyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: —CH═CH2, —CH═CH—CH3, —CH2—CH═CH2, —CH═CH—CH2—CH3, —CH═CH—CH═CH2, or e.g. —CH═CH—, when two moieties of a molecule are linked by the alkenyl group.
Each hydrogen of a C2_6 alkenyl carbon may be replaced by a substituent as further specified. “C2-6 alkynyl” means an alkynyl chain having 2 to 6 carbon atoms, e.g. if present at the end of a molecule: —C≡CH, —CH2—C≡CH, CH2—CH2—C≡CH, CH2—C≡C≡CH3, or e.g. —C═C— when two moieties of a molecule are linked by the alkynyl group. Each hydrogen of a C2-6 alkynyl carbon may be replaced by a substituent as further specified.
“C3-7 cycloalkyl” or “C3-7 cycloalkyl ring” means a cyclic alkyl chain having 3-7 carbon atoms, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Preferably, cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. Each hydrogen of a cycloalkyl carbon may be replaced by a substituent as further specified herein. The term “C3-5 cycloalkyl” or “C3-5 cycloalkyl ring” is defined accordingly.
“C5 cycloalkylene” refers to a bivalent cycloalkyl with five carbon atoms, i.e. a bivalent cyclopentyl ring.
“C5 cycloalkenylene” refers to a bivalent cycloalkenylene, i.e. a bivalent cyclopentene or cyclopentadiene.
“C4-12 bicycloalkyl” or “C4-12 bicycloalkyl ring” means a bicyclic fused, bridged or spiro alkyl chain having 4 to 12 carbon atoms, e.g. hexahydroindane, Octahydropentalen, bicycle[2.2.1]heptane or spiro(3.2)hexane. Each hydrogen of a bicycloalkyl carbon may be replaced by a substituent as further specified herein.
“Halogen” means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
“3 to 7 membered heterocyclyl” or “3 to 7 membered heterocycle” means a ring with 3, 4, 5, 6 or 7 ring atoms that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 4 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 3 to 7 membered heterocycle are aziridine, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetrahydropyran, imidazolidine, pyridine, pyridazine, pyrazine, pyrimidine, piperazine, piperidine, morpholine, tetrazole, triazole, triazolidine, tetrazolidine, diazepane, azepine or homopiperazine. The term “5 to 6 membered heterocyclyl” or “5 to 6 membered heterocycle” is defined accordingly and and includes 5 to 6 membered aromatic heterocyclyl or heterocycle. The term “5 membered heterocyclyl” or “5 membered heterocycle” is defined accordingly and includes 5 membered aromatic heterocyclyl or heterocycle.
The term “nitrogen ring atom containing 5-membered heterocyclene” refers to a bivalent 5-membered heterocycle, wherein at least one of the five ring atoms is a nitrogen atom and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom.
“Saturated 4 to 7 membered heterocyclyl” or “saturated 4 to 7 membered heterocycle” means fully saturated “4 to 7 membered heterocyclyl” or “4 to 7 membered heterocycle”.
“4 to 7 membered at least partly saturated heterocyclyl” or “4 to 7 membered at least partly saturated heterocycle” means an at least partly saturated “4 to 7 membered heterocyclyl” or “4 to 7 membered heterocycle”.
“5 to 6 membered aromatic heterocyclyl” or “5 to 6 membered aromatic heterocycle” means a heterocycle derived from cyclopentadienyl or benzene, where at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—). Examples for such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole, pyridine, pyrimidine, pyridazine, pyrazine, triazine.
“5 membered aromatic heterocyclyl” or “5 membered aromatic heterocycle” means a heterocycle derived from cyclopentadienyl, where at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—). Examples for such heterocycles are furan, thiophene, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, triazole, tetrazole. “6 membered aromatic heterocyclyl” or “6 membered aromatic heterocycle” means a heterocycle derived from benzene, where at least one carbon atom is replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—). Examples for such heterocycles are pyridine, pyrimidine, pyridazine, pyrazine, triazine.
“7 to 12 membered heterobicyclyl” or “7 to 12 membered heterobicycle” means a heterocyclic system of two rings with 7 to 12 ring atoms, where at least one ring atom is shared by both rings and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for a 7 to 12 membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine or pteridine. The term 7 to 12 membered heterobicycle also includes spiro structures of two rings like 6-oxa-2-azaspiro[3,4]octane, 2-oxa-6-azaspiro[3.3]heptan-6-yl or 2,6-diazaspiro[3.3]heptan-6-yl or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane or 2,5-diazabicyclo[2.2.2]octan-2-yl or 3,8-diazabicyclo[3.2.1] octane.
“Saturated 7 to 12 membered heterobicyclyl” or “saturated 7 to 12 membered heterobicycle” means fully saturated “7 to 12 membered heterobicyclyl” or “7 to 12 membered heterobicycle”.
“7 to 12 membered at least partly saturated heterobicyclyl” or “7 to 12 membered at least partly saturated heterobicycle” means an at least partly saturated “7 to 12 membered heterobicyclyl” or “7 to 12 membered heterobicycle”.
“9 to 11 membered aromatic heterobicyclyl” or “9 to 11 membered aromatic heterobicycle” means a heterocyclic system of two rings, wherein at least one ring is aromatic and wherein the heterocyclic ring system has 9 to 11 ring atoms, where two ring atoms are shared by both rings and that may contain up to the maximum number of double bonds (fully or partially aromatic) wherein at least one ring atom up to 6 ring atoms are replaced by a heteroatom selected from the group consisting of sulfur (including —S(O)—, —S(O)2—), oxygen and nitrogen (including ═N(O)—) and wherein the ring is linked to the rest of the molecule via a carbon or nitrogen atom. Examples for an 9 to 11 membered aromatic heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, dihydroquinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, dihydro-isoquinoline, benzazepine, purine or pteridine. The terms “9 to 10 membered aromatic heterobicyclyl” or “9 to 10 membered aromatic heterobicycle” are defined accordingly.
Preferred compounds of formula (I) are those compounds in which one or more of the residues contained therein have the meanings given above or below, with all combinations of preferred substituent definitions being a subject of the present invention. With respect to all preferred compounds of the formula (I) the present invention also includes all tautomeric and stereoisomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts.
In preferred embodiments of the present invention, the substituents mentioned below independently have the following meaning. Hence, one or more of these substituents can have the preferred or more preferred meanings given below.
In one preferred embodiment of the present invention, for the compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, X1 is N(R4) and X2 is CH(R4e) to give formula (I-1)
In another preferred embodiment of the present invention, for the compound of formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof, X1 and X2 are O to give formula (1-2)
Preferably, R4 is H, CH3, CH2CH3, or CH2CH2OCH3; more preferably, H or CH3; even more preferably H.
Preferably, R4a, R4b, R4c, R4f are independently selected from the group consisting of H, halogen and C1-4 alkyl and R4d, R4e are independently selected from the group consisting of H, OH, OC1-4 alkyl, halogen and C1-4 alkyl; more preferably R4a, R4b, R4c, R4f, R4d, R4e are independently selected from the group consisting of H, F and CH3; even more preferably R4a, R4b, R4c, R4f, R4d, R4e are H.
Preferably, R1 is H or CH3; more preferably H.
Preferably, R1, R4, R4a, R4b, R4c, R4f, R4d, R4e in formula (I-1) are H to give formula (Ia-1)
It is also preferred that R1, R4a, R4b, R4c, R4f, R4d in formula (I-2) are H to give formula (Ia-2)
R2 is phenyl, naphthyl, C3-7 cycloalkyl, 3 to 7 membered heterocyclyl or 7 to 12 membered heterobicyclyl, wherein R2 is optionally substituted with one or more R5, which are the same or different, provided that, if a ring atom of R2 bound to the ring atom attaching R2 to the carbon atom of the amide group shown in formula (I) is an oxygen, then the ring atom attaching R2 to the carbon atom of the amide group is not substituted with H or F.
Thus, in case a ring atom of R2 bound to the ring atom attaching R2 to the carbon atom of the amide group shown in formula (I) is an oxygen, the ring atom attaching R2 to the carbon atom of the amide group is not substituted with H or F as defined in formulas (I) of WO 2020/216766 A1 and PCT/EP2021/056023 for R2a. Preferably, all ring atoms of R2 bound to the ring atom attaching R2 to the carbon atom of the amide group shown in formula (I) are other than oxygen. More preferably, all ring atoms of R2 are other than oxygen.
Preferably, R2 is phenyl, pyridyl, thiophenyl, 1H-indolyl, quinolinyl, isoquinolinyl, quinazolinyl, pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-a]pyrazinyl, indolizinyl, chromenyl, benzofuranyl or 2H-1,3-benzodioxolyl; more preferably phenyl, pyridin-2-yl, pyridin-3-yl, thiophen-2-yl, 1H-indol-2-yl, quinolin-2-yl, quinolin-3-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-3-yl, quinazolin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrrolo[1,2-a]pyrazin-3-yl, indolizin-2-yl, chromen-3-yl, benzofuran-2-yl or 2H-1,3-benzodioxol-5-yl; and wherein R2 is optionally substituted with one or more R5, which are the same or different, provided that, if a ring atom of R2 bound to the ring atom attaching R2 to the carbon atom of the amide group shown in formula (I) is an oxygen, then the ring atom attaching R2 to the carbon atom of the amide group is not substituted with H or F. More preferably, R2 is quinolinyl, especially quinolin-2-yl, quinolin-3-yl, quinolin-6-yl, quinolin-7-yl, wherein R2 is optionally substituted with one or more R5, which are the same or different.
Preferably, R2 is substituted with one, two or three R5, which are the same or different.
Preferably, R5 is F, Cl, CH3, CF3, OCF3 or OCH2CF3.
Preferably, R3 is OR9 and R9 is C1-6 alkyl or C2-6 alkenyl, wherein C1-6 alkyl and C2-6 alkenyl are substituted with one or more R11, which are the same or different.
Preferably, R3 is OR9 and R9 is C1-6 alkyl, preferably ethyl, wherein C1-6 alkyl is substituted with one R11.
Preferably, R3 is OCH2CH2OCF3.
Preferably, R3 is OR9 and R9 is C1-6 alkyl or C2-6 alkenyl, preferably but-2-enyl, wherein C1-6 alkyl and C2-6 alkenyl are each substituted with three F; more preferably R3 is OCH2CH═CHCF3.
Preferably, R3 is A1, preferably phenyl or cyclobutyl, wherein A1 is optionally substituted with one or more R13, which are the same or different.
Preferably, A1 is substituted with one or two, preferably one R1.
Preferably, R13 is CH3, CHF2, CF3, CH2CF3, OCHF2, OCH2CF3, OCF3, OCH3, F or Cl, more preferably Cl or OCF3.
Compounds of the formula (I) in which some or all of the above-mentioned groups have the preferred or more preferred meanings are also an object of the present invention.
For preferred specific compounds or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof of the present invention R1, R2, R3, R4a, R4b, R4c, R4d, R4f, X1, X2 in formula (I) are selected to give
Where tautomerism, like e.g. keto-enol tautomerism, of compounds of formula (I) may occur, the individual forms, like e.g. the keto and enol form, are comprised separately and together as mixtures in any ratio. Same applies to stereoisomers, like e.g. enantiomers, cis/trans isomers, conformers and the like.
Especially, when enantiomeric or diastereomeric forms are given in a compound according to formula (I) each pure form separately and any mixture of at least two of the pure forms in any ratio is comprised by formula (I) and is a subject of the present invention.
A preferred compound is a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof of formula (I) with a relative configuration as shown in formula (Ib)
More preferably, the configuration of a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof of formula (I) is shown in formulas (Ib-1) (Ib-2), (Ib-3) and (Ib-4)
Isotopic labeled compounds of formula (I) are also within the scope of the present invention. Methods for isotope labeling are known in the art. Preferred isotopes are those of the elements H, C, N, O and S. Solvates and hydrates of compounds of formula (I) are also within the scope of the present invention.
If desired, isomers can be separated by methods well known in the art, e.g. by liquid chromatography. Same applies for enantiomers by using e.g. chiral stationary phases. Additionally, enantiomers may be isolated by converting them into diastereomers, i.e. coupling with an enantiomerically pure auxiliary compound, subsequent separation of the resulting diastereomers and cleavage of the auxiliary residue. Alternatively, any enantiomer of a compound of formula (I) may be obtained from stereoselective synthesis using optically pure starting materials, reagents and/or catalysts.
In case the compounds according to formula (I) contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the formula (I) which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. Compounds of the formula (I) which contain one or more basic groups, i.e. groups which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples for suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the formula (I) simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts according to the formula (I) can be obtained by customary methods which are known to the person skilled in the art like, for example by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the formula (I) which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
As shown below compounds of the present invention are believed to be suitable for modulating the integrated stress response pathway.
The Integrated Stress Response (ISR) is a cellular stress response common to all eukaryotes (1). Dysregulation of ISR signaling has important pathological consequences linked inter alia to inflammation, viral infection, diabetes, cancer and neurodegenerative diseases.
ISR is a common denominator of different types of cellular stresses resulting in phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) on serine 51 leading to the suppression of normal protein synthesis and expression of stress response genes (2). In mammalian cells the phosphorylation is carried out by a family of four eIF2alpha kinases, namely: PKR-like ER kinase (PERK), double-stranded RNA-dependent protein kinase (PKR), heme-regulated eIF2alpha kinase (HRI), and general control non-derepressible 2 (GCN2), each responding to distinct environmental and physiological stresses (3).
eIF2alpha together with eIF2beta and eIF2gamma form the eIF2 complex, a key player of the initiation of normal mRNA translation (4). The eIF2 complex binds GTP and Met-tRNA; forming a ternary complex (eIF2-GTP-Met-tRNAi), which is recruited by ribosomes for translation initiation (5, 6).
eIF2B is a heterodecameric complex consisting of 5 subunits (alpha, beta, gamma, delta, epsilon) which in duplicate form a GEF-active decamer (7).
In response to ISR activation, phosphorylated eIF2alpha inhibits the eIF2B-mediated exchange of GDP for GTP, resulting in reduced ternary complex formation and hence in the inhibition of translation of normal mRNAs characterized by ribosomes binding to the 5′ AUG start codon (8). Under these conditions of reduced ternary complex abundance the translation of several specific mRNAs including the mRNA coding for the transcription factor ATF4 is activated via a mechanism involving altered translation of upstream ORFs (uORFs) (7, 9, 10). These mRNAs typically contain one or more uORFs that normally function in unstressed cells to limit the flow of ribosomes to the main coding ORF. For example, during normal conditions, uORFs in the 5′ UTR of ATF occupy the ribosomes and prevent translation of the coding sequence of ATF4. However, during stress conditions, i.e. under conditions of reduced ternary complex formation, the probability for ribosomes to scan past these upstream ORFs and initiate translation at the ATF4 coding ORF is increased. ATF4 and other stress response factors expressed in this way subsequently govern the expression of an array of further stress response genes. The acute phase consists in expression of proteins that aim to restore homeostasis, while the chronic phase leads to expression of pro-apoptotic factors (1, 11, 12, 13).
Upregulation of markers of ISR signaling has been demonstrated in a variety of conditions, among these cancer and neurodegenerative diseases. In cancer, ER stress-regulated translation increases tolerance to hypoxic conditions and promotes tumor growth (14, 15, 16), and deletion of PERK by gene targeting has been shown to slow growth of tumours derived from transformed PERK−/− mouse embryonic fibroblasts (14, 17). Further, a recent report has provided proof of concept using patient derived xenograft modeling in mice for activators of eIF2B to be effective in treating a form of aggressive metastatic prostate cancer (28). Taken together, prevention of cytoprotective ISR signaling may represent an effective anti-proliferation strategy for the treatment of at least some forms of cancer.
Further, modulation of ISR signaling could prove effective in preserving synaptic function and reducing neuronal decline, also in neurodegenerative diseases that are characterized by misfolded proteins and activation of the unfolded protein response (UPR), such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD) and Jakob Creutzfeld (prion) diseases (18, 19, 20). With prion disease an example of a neurodegenerative disease exists where it has been shown that pharmacological as well as genetic inhibition of ISR signaling can normalize protein translation levels, rescue synaptic function and prevent neuronal loss (21). Specifically, reduction of levels of phosphorylated eIF2alpha by overexpression of the phosphatase controlling phosphorylated eIF2alpha levels increased survival of prion-infected mice whereas sustained eIF2alpha phosphorylation decreased survival (22).
Further, direct evidence for the importance of control of protein expression levels for proper brain function exists in the form of rare genetic diseases affecting functions of eIF2 and eIF2B. A mutation in eIF2gamma that disrupts complex integrity of eIF2 and hence results in reduced normal protein expression levels is linked to intellectual disability syndrome (ID) (23). Partial loss of function mutations in subunits of eIF2B have been shown to be causal for the rare leukodystrophy Vanishing White Matter Disease (VWMD) (24, 25). Specifically, stabilization of eIF2B partial loss of function in a VWMD mouse model by a small molecule related to ISRIB has been shown to reduce ISR markers and improve functional as well as pathological end points (26, 27).
The present invention provides compounds of the present invention in free or pharmaceutically acceptable salt form or in the form of solvates, hydrates, tautomers or stereoisomers to be used in the treatment of diseases or disorders mentioned herein. The same applies to a pharmaceutical composition of the present invention.
Thus an aspect of the present invention is a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof of the present invention for use as a medicament. The same applies to a pharmaceutical composition of the present invention.
The therapeutic method described may be applied to mammals such as dogs, cats, cows, horses, rabbits, monkeys and humans. Preferably, the mammalian patient is a human patient.
Accordingly, the present invention provides a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention to be used in the treatment or prevention of one or more diseases or disorders associated with integrated stress response.
A further aspect of the present invention is a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention for use in a method of treating or preventing one or more disorders or diseases associated with integrated stress response.
A further aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention for the manufacture of a medicament for the treatment or prophylaxis of one or more disorders or diseases associated with integrated stress response.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases or disorders associated with integrated stress response, wherein the method comprises administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention.
The present invention provides a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention to be used in the treatment or prevention of one or more diseases or disorders mentioned below.
A further aspect of the present invention is a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention for use in a method of treating or preventing one or more disorders or diseases mentioned below.
A further aspect of the present invention is the use of a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention for the manufacture of a medicament for the treatment or prophylaxis of one or more disorders or diseases mentioned below.
Yet another aspect of the present invention is a method for treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases or disorders mentioned below, wherein the method comprises administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof or a pharmaceutical composition of the present invention.
Diseases or disorders include but are not limited to leukodystrophies, intellectual disability syndrome, neurodegenerative diseases and disorders, neoplastic diseases, infectious diseases, inflammatory diseases, musculoskeletal diseases, metabolic diseases, ocular diseases as well as diseases selected from the group consisting of organ fibrosis, chronic and acute diseases of the liver, chronic and acute diseases of the lung, chronic and acute diseases of the kidney, myocardial infarction, cardiovascular disease, arrhythmias, atherosclerosis, spinal cord injury, ischemic stroke, and neuropathic pain.
Examples of leukodystrophies include, but are not limited to, Vanishing White Matter Disease (VWMD) and childhood ataxia with CNS hypo-myelination (e.g. associated with impaired function of eIF2 or components in a signal transduction or signaling pathway including eIF2).
Intellectual disability in particular refers to a condition in which a person has certain limitations in intellectual functions like communicating, taking care of him- or herself, and/or has impaired social skills. Intellectual disability syndromes include, but are not limited to, intellectual disability conditions associated with impaired function of eIF2 or components in a signal transduction or signaling pathway including eIF2.
Examples of neurodegenerative diseases and disorders include, but are not limited to, Alexander's disease, Alper's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, Ataxia telangiectasia, Batten disease (also known as Spielmeyer-Vogt-Sjogren-Batten disease), Bovine spongiform encephalopathy (BSE), Canavan disease, Cockayne syndrome, Corticobasal degeneration, Creutzfeldt-Jakob disease, frontotemporal dementia, Gerstmann-Straussler-Scheinker syndrome, Huntington's disease, HIV-associated dementia, Kennedy's disease, Krabbe's disease, Kuru, Lewy body dementia, Machado-Joseph disease (Spinocerebellar ataxia type 3), Multiple sclerosis, Multiple System Atrophy, Narcolepsy, Neuroborreliosis, Parkinson's disease, Pelizaeus-Merzbacher Disease, Pick's disease, Primary lateral sclerosis, Prion diseases, Progressive supranuclear palsy, Refsum's disease, Sandhoffs disease, Schilder's disease, Subacute combined degeneration of spinal cord secondary to Pernicious Anaemia, Schizophrenia, Spinocerebellar ataxia (multiple types with varying characteristics), Spinal muscular atrophy, Steele-Richardson-Olszewski disease, Tabes dorsalis, and tauopathies.
In particular, the neurodegenerative disease or and disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
A neoplastic disease may be understood in the broadest sense as any tissue resulting from miss-controlled cell growth. In many cases a neoplasm leads to at least bulky tissue mass optionally innervated by blood vessels. It may or may not comprise the formation of one or more metastasis/metastases. A neoplastic disease of the present invention may be any neoplasm as classified by the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) classes C00-D48.
Exemplarily, a neoplastic disease according to the present invention may be the presence of one or more malignant neoplasm(s) (tumors) (ICD-10 classes C00-C97), may be the presence of one or more in situ neoplasm(s) (ICD-10 classes D00-D09), may be the presence of one or more benign neoplasm(s) (ICD-10 classes D10-D36), or may be the presence of one or more neoplasm(s) of uncertain or unknown behavior (ICD-10 classes D37-D48). Preferably, a neoplastic disease according to the present invention refers to the presence of one or more malignant neoplasm(s), i.e., is malignant neoplasia (ICD-10 classes C00-C97).
In a more preferred embodiment, the neoplastic disease is cancer.
Cancer may be understood in the broadest sense as any malignant neoplastic disease, i.e., the presence of one or more malignant neoplasm(s) in the patient. Cancer may be solid or hematologic malignancy. Contemplated herein are without limitation leukemia, lymphoma, carcinomas and sarcomas.
In particular, neoplastic diseases, such as cancers, characterized by upregulated ISR markers are included herein.
Exemplary cancers include, but are not limited to, thyroid cancer, cancers of the endocrine system, pancreatic cancer, brain cancer (e.g. glioblastoma multiforme, glioma), breast cancer (e.g. ER positive, ER negative, chemotherapy resistant, herceptin resistant, HER2 positive, doxorubicin resistant, tamoxifen resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), cervix cancer, ovarian cancer, uterus cancer, colon cancer, head & neck cancer, liver cancer (e.g. hepatocellular carcinoma), kidney cancer, lung cancer (e.g. non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), colon cancer, esophageal cancer, stomach cancer, bladder cancer, bone cancer, gastric cancer, prostate cancer and skin cancer (e.g. melanoma).
Further examples include, but are not limited to, myeloma, leukemia, mesothelioma, and sarcoma.
Additional examples include, but are not limited to, Medulloblastoma, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, Paget's Disease of the Nipple, Phyllodes Tumors, Lobular Carcinoma, Ductal Carcinoma, cancer of the pancreatic stellate cells, and cancer of the hepatic stellate cells.
Exemplary leukemias include, but are not limited to, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophylic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocyte leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblasts leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, and undifferentiated cell leukemia.
Exemplary sarcomas include, but are not limited to, chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, and telangiectaltic sarcoma.
Exemplary melanomas include, but are not limited to, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, and superficial spreading melanoma.
Exemplary carcinomas include, but are not limited to, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, ductal carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatiniforni carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lobular carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tubular carcinoma, tuberous carcinoma, verrucous carcinoma, and carcinoma villosum.
Examples include, but are not limited to, infections caused by viruses (such as infections by HIV-1: human immunodeficiency virus type 1; IAV: influenza A virus; HCV: hepatitis C virus; DENV: dengue virus; ASFV: African swine fever virus; EBV: Epstein-Barr virus; HSV1: herpes simplex virus 1; CHIKV: chikungunya virus; HCMV: human cytomegalovirus; SARS-CoV: severe acute respiratory syndrome coronavirus; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2) and infections caused by bacteria (such as infections by Legionella, Brucella, Simkania, Chlamydia, Helicobacter and Campylobacter).
Examples of inflammatory diseases include, but are not limited to, postoperative cognitive dysfunction (decline in cognitive function after surgery), traumatic brain injury, arthritis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), myasthenia gravis, juvenile onset diabetes, diabetes mellitus type 1, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, ankylosing spondylitis, psoriasis, Sjogren's syndrome, vasculitis, glomerulonephritis, auto-immune thyroiditis, Behcet's disease, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, ichthyosis, Graves ophthalmopathy, inflammatory bowel disease, Addison's disease, Vitiligo, asthma, allergic asthma, acne vulgaris, celiac disease, chronic prostatitis, inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, sarcoidosis, transplant rejection, interstitial cystitis, atherosclerosis, and atopic dermatitis.
Musculoskeletal Diseases Examples of musculoskeletal diseases include, but are not limited to, muscular dystrophy, multiple sclerosis, Freidrich's ataxia, a muscle wasting disorder (e.g., muscle atrophy, sarcopenia, cachexia), inclusion body myopathy, progressive muscular atrophy, motor neuron disease, carpal tunnel syndrome, epicondylitis, tendinitis, back pain, muscle pain, muscle soreness, repetitive strain disorders, and paralysis.
Examples of metabolic diseases include, but are not limited to, diabetes (in particular diabetes Type II), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), Niemann-Pick disease, liver fibrosis, obesity, heart disease, atherosclerosis, arthritis, cystinosis, phenylketonuria, proliferative retinopathy, and Kearns-Sayre disease.
Examples of ocular diseases include, but are not limited to, edema or neovascularization for any occlusive or inflammatory retinal vascular disease, such as rubeosis irides, neovascular glaucoma, pterygium, vascularized glaucoma filtering blebs, conjunctival papilloma; choroidal neovascularization, such as neovascular age-related macular degeneration (AMD), myopia, prior uveitis, trauma, or idiopathic; macular edema, such as post surgical macular edema, macular edema secondary to uveitis including retinal and/or choroidal inflammation, macular edema secondary to diabetes, and macular edema secondary to retinovascular occlusive disease (i.e. branch and central retinal vein occlusion); retinal neovascularization due to diabetes, such as retinal vein occlusion, uveitis, ocular ischemic syndrome from carotid artery disease, ophthalmic or retinal artery occlusion, sickle cell retinopathy, other ischemic or occlusive neovascular retinopathies, retinopathy of prematurity, or Eale's Disease; and genetic disorders, such as VonHippel-Lindau syndrome.
Further Diseases
Further diseases include, but are not limited to, organ fibrosis (such as liver fibrosis, lung fibrosis, or kidney fibrosis), chronic and acute diseases of the liver (such as fatty liver disease, or liver steatosis), chronic and acute diseases of the lung, chronic and acute diseases of the kidney, myocardial infarction, cardiovascular disease, arrhythmias, atherosclerosis, spinal cord injury, ischemic stroke, and neuropathic pain.
Yet another aspect of the present invention is a pharmaceutical composition comprising at least one compound or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof of the present invention together with a pharmaceutically acceptable carrier, optionally in combination with one or more other bioactive compounds or pharmaceutical compositions.
Preferably, the one or more bioactive compounds are modulators of the integrated stress response pathway other than compounds of formula (I).
“Pharmaceutical composition” means one or more active ingredients, and one or more inert ingredients that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.
A pharmaceutical composition of the present invention may comprise one or more additional compounds as active ingredients like a mixture of compounds of formula (I) in the composition or other modulators of the integrated stress response pathway.
The active ingredients may be comprised in one or more different pharmaceutical compositions (combination of pharmaceutical compositions).
The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids.
The compositions include compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
In practical use, the compounds of formula (I) can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as powders, hard and soft capsules and tablets, with the solid oral preparations being preferred over the liquid preparations.
Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally, for example, as liquid drops or spray.
The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.
Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.
Compounds of formula (I) may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropyl-cellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form should be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of formula (I) are administered orally.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
Starting materials for the synthesis of preferred embodiments of the invention may be purchased from commercially available sources such as Array, Sigma Aldrich, Acros, Fisher, Fluka, ABCR or can be synthesized using known methods by one skilled in the art.
In general, several methods are applicable to prepare compounds of the present invention. In some cases various strategies can be combined. Sequential or convergent routes may be used. Exemplary synthetic routes are described below.
The following Abbreviations and Acronyms are used:
Analytical (MET/CR/1410) HPLC-MS were performed on a Shimadzu LCMS systems using a Kinetex Core shell C18 column (2.1 mm×50 mm, 5 μm; temperature: 40° C.) and a gradient of 5-100% B (A=0.1% formic acid in H2O; B=0.1% formic acid in ACN) over 1.2 min then 100% B for 0.1 min. A second gradient of 100-5% B was then applied over 0.01 min with an injection volume of 3 μL at a flow rate of 1.2 mL/min. UV spectra were recorded at 215 nm using a SPD-M20A photo diode array detector spectrum range: 200-400 nm. Mass spectra were obtained using a 2010EV detector. Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort software.
Analytical (MET/uPLC/1704) uHPLC-MS were performed on a Waters Acquity uPLC system using a Waters UPLC® BEH™ C18 column (2.1 mm×50 mm, 1.7 μm; temperature 40° C.) and a gradient of 5-100% B (A=0.1% formic acid in H2O; B=0.10% formic acid in ACN) over 1.1 min then 100% B for 0.25 min. A second gradient of 100-5% B was then applied over 0.05 min and held for 0.1 min with an injection volume of 1 μL at a flow rate of 0.9 mL/min. UV spectra were recorded at 215 nm on a Waters Acquity PDA with a spectrum range of 200-400 nm. Mass spectra were obtained using a Waters QDa. Data were integrated and reported using Waters MassLynx and OpenLynx software.
Analytical (MET/CR/1602) uHPLC-MS were performed on a Waters Acquity uPLC system using Waters UPLC® BEH™ C18 column (2.1 mm×30 mm, 1.7 μm; temperature 40° C.) and a gradient of 5-100% B (A: 2 mM ammonium bicarbonate, buffered to pH 10, B: ACN) over 0.75 min, then 100% B for 0.1 min. A second gradient of 100-5% B was then applied over 0.05 min and held for 0.1 min with an injection volume of 1 μL at a flow rate of 1 mL/min. UV spectra were recorded at 215 nm on a Waters Acquity PDA with a spectrum range of 200-400 nm. Mass spectra were obtained using a Waters Quattro Premier XE. Data were integrated and reported using Waters MassLynx and OpenLynx software.
Analytical (MET/uPLC/AB101) uHPLC-MS were performed on a Waters Acquity uPLC system using a Phenomenex Kinetex-XB C18 column (2.1 mm×100 mm, 1.7 μM; temperature: 40° C.) and a gradient of 5-100% B (A=0.1% formic acid in H2O; B=0.1% formic acid in ACN) over 5.3 min then 100% B for 0.5 min. A second gradient of 100-5% B was then applied over 0.02 min and held for 1.18 min with an injection volume of 1 μL at flow rate of 0.6 mL/min. UV spectra were recorded at 215 nm using a Waters Acquity PDA detector spectrum range: 200-400 nm. Mass spectra were obtained using a Waters SQD (MSQ1) or Waters Acquity QDA (MSQ2). Data were integrated and reported using Waters MassLynx and OpenLynx software.
Analytical (MET/CR/1416) HPLC-MS were performed on Shimadzu LCMS systems using a Waters Atlantis dC18 column (2.1 mm×100 mm, 3 μm; temperature: 40° C.) and a gradient of 5-100% B (A=0.1% formic acid in H2O; B=0.10% formic acid in ACN) over 5 min then 100% B for 0.4 min. A second gradient of 100-5% B was then applied over 0.02 min and held for 1.58 min with an injection volume of 3 μL at flow rate of 0.6 mL/min. UV spectra were recorded at 215 nm using a SPD-M20A photo diode array detector spectrum range: 200-400 nm. Mass spectra were obtained using a 2010EV detector. Data were integrated and reported using Shimadzu LCMS-Solutions and PsiPort software.
Analytical (MET/uHPLC/AB105) uPLC-MS were performed on a Waters Acquity uPLC system using a Waters UPLC® BEH™ C18 column (2.1 mm×100 mm, 1.7 μm column; temperature: 40° C.) and a gradient of 5-100% (A=2 mM ammonium bicarbonate, buffered to pH 10; B=ACN) over 5.3 min then 100% B for 0.5 min. A second gradient of 100-5% B was then applied over 0.02 min and held for 1.18 min with an injection volume of 1 μL and at flow rate of 0.6 mL/min. UV spectra were recorded at 215 nm using a Waters Acquity photo diode array detector Spectrum range: 200-400 nm. Mass spectra were obtained using a Waters Quattro Premier XE mass detector. Data were integrated and reported using Waters MassLynx and OpenLynx software.
Purifications (P1) LC were performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm×100 mm, 10 μM; temperature: r.t.) and a gradient of 10-95% B (A=0.1% formic acid in H2O; B=0.1% formic acid in ACN) over 14.44 min then 95% B for 2.11 min. A second gradient of 95-10% B was then applied over 0.2 min with an injection volume of 1500 μL at flow rate of 40 mL/min. UV spectra were recorded at 215 nm using a Gilson detector.
Purifications (P2) LC were performed on a Gilson LC system using a Waters Sunfire C18 column (30 mm×10 mm, 10 μM; temperature: r.t.) and a gradient of 30-95% B (A=0.1% formic acid in water; B=0.1% formic acid in ACN) over 11.00 min then 95% B for 2.10 min. A second gradient of 95-30% B was then applied over 0.2 min with an injection volume of 1500 μL at flow rate of 40 mL/min. UV spectra were recorded at 215 nm using a Gilson detector.
Purifications (P3) LC were performed on a Gilson LC system using a Waters X-Bridge C18 column (30 mm×100 mm, 10 μM; temperature: r.t.) and a gradient of 10-95% B (A=0.2% NH4OH in H2O; B=0.2% NH4OH in ACN) over 14.44 min then 95% B for 2.11 min. A second gradient of 95-10% B was then applied over 0.2 min with an injection volume of 1500 μL at flow rate of 40 mL/min. UV spectra were recorded at 215 nm using a Gilson detector.
Purifications (P4) LC were performed on a Gilson LC system using a Waters X-Bridge C18 column (30 mm×10 mm, 10 μM; temperature: r.t.) and a gradient of 30-95% B (A=0.2% NH4OH in water; B=0.2% NH4OH in ACN) over 11.00 min then 95% B for 2.10 min. A second gradient of 95-30% B was then applied over 0.21 min with an injection volume of 1500 μL at flow rate of 40 mL/min. UV spectra were recorded at 215 nm using a Gilson detector.
Purifications by FCC on reverse phase silica (acidic pH, standard elution method) were performed on Biotage Isolera systems using the appropriate SNAP C18 cartridge and a gradient of 10% B (A=0.1% formic acid in H2O; B=0.1% formic acid in ACN) over 1.7 CV then 10-100% B over 19.5 CV and 100% B for 2 CV.
Purifications by FCC on reverse phase silica (basic pH, standard elution method) were performed on Biotage Isolera systems using the appropriate SNAP C18 cartridge and a gradient of 10% B (A=0.1% NH3 in H2O; B=0.1% NH3 in ACN) over 1.7 CV then 10-100% B over 19.5 CV and 100% B for 2 CV.
Unless otherwise stated, 1H NMR spectra were recorded at 500 MHz, 400 MHz or 250 MHz on either a Bruker Avance III HD 500 MHz spectrometer, Bruker Avance III HD 400 MHz spectrometer or Bruker Avance III HD 250 MHz spectrometer respectively. Chemical shifts, δ, are quoted in parts per million (ppm) and are referenced to the residual solvent peak. The following abbreviations are used to denote the multiplicities and general assignments: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), dq (doublet of quartets), hep (heptet), m (multiplet), pent (pentet), td (triplet of doublets), qd (quartet of doublets), app. (apparent) and br. (broad). Coupling constants, J, are quoted to the nearest 0.1 Hz.
All the compounds have been synthesised with a purity equal or greater 95% unless otherwise specified.
DMSO (75 mL) was added to a solution of TMSOI (12.9 g, 58.3 mmol) and tBuOK (6.27 g, 55.9 mmol) in anhydrous THF (62 mL) and the solution was stirred at r.t for 1 h. The reaction mixture was cooled to −12° C. and a solution of ethyl Boc-D-Pyroglutamate (12.5 g, 48.6 mmol) in anhydrous THF (38 mL) was added and stirred at r.t. for 16 h. The reaction mixture was diluted with satd aq NH4Cl solution (78 mL), H2O (15 mL) and EtOAc (200 mL), and the organic layer was isolated, washed with brine and concentrated in vacuo to approximately 100 mL. A solution of BnONH2—HCl (8.14 g, 51.0 mmol) in EtOAc (62 mL) was added and the mixture was stirred at reflux for 2 h. The reaction mixture was cooled to r.t. and washed with H2O and brine. The organic extracts were concentrated in vacuo to afford the title compound (85% purity, 19.5 g, 40.1 mmol, 83% yield) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.16-7.33 (m, 5H), 5.01-5.06 (m, 2H), 3.95-4.30 (m, 5H), 2.32-2.50 (m, 2H), 1.98-2.13 (m, 1H), 1.75-1.92 (m, 1H), 1.30-1.40 (m, 9H), 1.12-1.24 (m, 3H).
To a solution of ethyl (2R)-5-[(benzyloxy)imino]-2-{[(tert-butoxy)carbonyl]amino}-6-chlorohexanoate (85% purity, 19.5 g, 40.1 mmol) in EtOAc (157 mL) was added MsOH (7.8 mL, 0.12 mol) and the mixture was stirred at 42° C. for 2 h. The reaction mixture was added to a solution of KHCO3 (20.1 g, 0.201 mol) in H2O (100 mL) and the mixture was stirred at 52° C. for 2 h. The solution was cooled to r.t. and the organic layer was isolated, washed with brine, dried over Na2SO4, and concentrated in vacuo to afford the title compound (85% purity, 13.0 g, 40.0 mmol) in quantitative yield as a dark orange oil; 1H NMR (400 MHz, CDCl3) δ 7.20-7.34 (m, 5H), 4.99 (d, J=4.8 Hz, 2H), 4.13 (q, J=7.1 Hz, 2H), 3.45-3.56 (m, 1H), 3.25 (dd, J=14.9, 9.8 Hz, 1H), 3.08 (dt, J=14.5, 4.3 Hz, 1H), 2.01-2.32 (m, 3H), 1.55-1.80 (m, 1H), 1.21 (t, J=7.1 Hz, 3H).
Propanoic acid (23 mL, 0.240 mol) was added to a suspension of NaBH4 (3.03 g, 80.0 mmol) in EtOAc (95 mL) and the mixture was stirred at r.t for 1 h. The reaction mixture was added to a solution of ethyl (2R)-5-[(benzyloxy)imino]piperidine-2-carboxylate (85% purity, 13.0 g, 40.0 mmol) in EtOAc (95 mL) and H2SO4 (11 mL, 0.20 mol) at −20° C. and the mixture was stirred at r.t. for 60 h. The reaction mixture was diluted with H2O (75 mL) and neutralised using aq NH4OH solution. The organic layer was isolated, washed with brine, dried over Na2SO4, and concentrated to −75 mL volume. The solution was warmed to 45° C., and MeOH (30 mL) was added, followed by a solution of oxalic acid (3.60 g, 40.0 mmol) in MeOH (15 mL). The resulting mixture was cooled to 0° C., and the resultant precipitate was filtered under vacuum, and washed with MeOH/EtOH (1:4) and EtOAc, to afford the title compound (7.17 g, 19.1 mmol, 48% yield); 1H NMR (500 MHz, DMSO-d) 6=7.25-7.42 (m, 5H), 4.59 (s, 2H), 4.17-4.24 (m, 2H), 3.92 (dd, J=12.3, 3.2 Hz, 1H), 3.34-3.40 (m, 1H), 3.10 (ddd, J=15.1, 7.6, 3.9 Hz, 1H), 2.64 (t, J=11.5 Hz, 1H), 2.13 (dt, J=10.2, 3.4 Hz, 1H), 1.87 (dd, J=9.0, 3.8 Hz, 1H), 1.65 (qd, J=13.2, 3.6 Hz, 1H), 1.40 (qd, J=12.8, 3.9 Hz, 1H), 1.23 (t, J=7.1 Hz, 3H); M/Z: 279, [M+H]+, ESI+, RT=0.81 (S1).
To a solution of ethyl (2R,5S)-5-[(benzyloxy)amino]piperidine-2-carboxylate oxalic acid (4.8 g, 12.8 mmol) in anhydrous DCM (64 mL) at 0° C. was added Et3N (7.6 mL, 54.7 mmol) and DMAP (161 mg, 1.32 mmol), followed by Boc2O (8.9 mL, 38.7 mmol) and the mixture was stirred at r.t. for 17 h. The reaction mixture was diluted with satd aq NH4Cl solution, and the organic layer was isolated, washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel (0-40% EtOAc in heptane) to afford the title compound (3.37 g, 8.46 mmol, 66% yield) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.39-7.27 (m, 5H), 5.47 (s, 1H), 4.98-4.78 (m, 1H), 4.72 (q, J=11.5 Hz, 3H), 4.27-4.07 (m, 3H), 3.16 (s, 2H), 1.95 (s, 2H), 1.74-1.63 (m, 1H), 1.52 (s, 1H), 1.45 (s, 10H), 1.27 (t, J=7.1 Hz, 3H).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-[(benzyloxy)amino]piperidine-1,2-dicarboxylate (3.37 g, 8.46 mmol, Intermediate 1) in DCM (45 mL) at 0° C. was added DMAP (103 mg, 0.846 mmol), pyridine (1.44 mL, 16.92 mmol) and benzyl chloroformate (3.0 mL, 21.1 mmol) and the mixture was stirred at r.t. for 24 h. The reaction mixture was diluted with H2O (50 mL) and extracted with DCM (2×50 mL). The combined organic extracts were dried using a phase separator, concentrated in vacuo, and purified by chromatography on silica gel (0-30% EtOAc in heptane) to afford the title compound (3.97 g, 7.36 mmol, 87% yield) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.42-7.27 (m, 9H), 5.33-5.15 (m, 2H), 4.92-4.82 (m, 2H), 4.61-4.48 (m, 1H), 4.33-4.24 (m, 1H), 4.19 (q, J=7.1 Hz, 2H), 3.51 (dd, J=14.2, 5.0 Hz, 1H), 2.29-2.16 (m, 1H), 1.95-1.84 (m, 2H), 1.78-1.67 (m, 1H), 1.57-1.51 (m, 1H), 1.40 (s, 9H), 1.27 (t, J=7.1 Hz, 3H).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-[(benzyloxy)[(benzyloxy)carbonyl]amino]piperidine-1,2-dicarboxylate (3.97 g, 7.36 mmol) in MeOH (10 mL) and H2O (17 mL) was added 2 M aq LiOH solution (5.8 mL, 11.6 mmol) and the mixture was stirred at r.t. for 18 h. The reaction mixture was cooled to 0° C. and acidified to pH 2/3 using 1 M aq HCl solution. The aqueous solution was extracted with EtOAc (2×50 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by prep. HPLC (Method 5) to afford the title compound (3.24 g, 6.35 mmol, 82% yield) as an off-white solid; 1H NMR (400 MHz, CDCl3) δ 7.43-7.13 (m, 10H), 5.28-5.17 (m, 2H), 4.92-4.83 (m, 2H), 4.66-4.53 (m, 1H), 4.37-4.21 (m, 1H), 4.18-3.89 (m, 2H), 3.51 (dd, J=14.2, 4.9 Hz, 1H), 2.31-2.18 (m, 1H), 2.01-1.86 (m, 2H), 1.86-1.72 (m, 1H), 1.40 (s, 9H); M/Z: 483 [M−H]−, ESI−, RT=1.31 (S1).
To a solution of (2E)-4,4,4-trifluorobut-2-en-1-ol (1.00 g, 7.93 mmol) in DCM (5 mL) at 0° C. under N2 was added a solution of CDI (1.93 g, 11.9 mmol) in THF (8.5 mL). After 10 min the ice bath was removed and the reaction mixture was stirred at r.t. for 2.5 h. The mixture was transferred to a dropping funnel and added dropwise to a solution of hydrazine hydrate (80%, 2.0 mL, 31.7 mmol) at 0° C. over 20 min, and then stirred at r.t. overnight. The reaction mixture was diluted with H2O (50 mL) and the aqueous layer was extracted with EtOAc (3×20 mL). The combined organic extracts were washed with satd aq NaHCO3 solution (8×20 mL) and brine (20 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (1.02 g, 5.26 mmol, 66% yield) as a colourless oil; 1H NMR (500 MHz, CDCl3) δ 6.49-6.34 (m, 1H), 6.20 (s, 1H), 5.91-5.78 (m, 1H), 4.81-4.65 (m, 2H), 3.79 (s, 2H).
Intermediate compound in Table 1 was synthesised according to the general route 3 as exemplified by Intermediate 3 using the corresponding starting materials.
1H NMR Data
1H NMR (400 MHz, CDCl3) δ 6.06 (s, 1H), 4.47-4.25 (m, 2H), 4.23-4.06 (m, 2H), 3.76 (d, J = 3.3 Hz, 2H).
To a solution of (1s,3s)-3-(trifluoromethoxy)cyclobutane-1-carboxylic acid (87% purity, 2.00 g, 9.45 mmol) and DIPEA (3.5 mL, 19.9 mmol) in anhydrous DMF (18 mL) was added HATU (4.18 g, 11.0 mmol) and the mixture was stirred at r.t. for 10 min. tert-butyl hydrazinecarboxylate (1.31 g, 9.92 mmol) was added portionwise and the mixture was stirred at r.t. for 2 h. The reaction mixture was diluted with EtOAc (20 mL), and washed with H2O (2×20 mL) and brine (2×20 mL). The organic extracts were dried over MgSO4, concentrated in vacuo, and purified by chromatography on silica gel (0-10% MeOH in DCM). Product containing fractions were combined and concentrated in vacuo before further purification by chromatography on silica gel (IP-NH, 0-100% EtOAc in Heptane) to afford the title compound (2.09 g, 6.66 mmol, 70% yield) as a yellow oil; 1H NMR (500 MHz, DMSO-d6) δ 9.62 (s, 1H), 8.75 (s, 1H), 4.79 (p, J=7.6 Hz, 1H), 2.67-2.57 (m, 1H), 2.33-2.19 (m, 2H), 1.41 (s, 9H); M/Z: 199 [M-Boc+H]+, ESI+, RT=0.77 (S2).
(1s,3s)-N-[(tert-butoxy)carbonyl]-3-(trifluoromethoxy)cyclobutane-1-carbohydrazide (2.09 g, 6.66 mmol) was dissolved in 4 M HCl in 1,4-dioxane (21 mL) and stirred at r.t. overnight. The reaction mixture was concentrated in vacuo and the residue was suspended in DCM and stirred, then the solid was filtered, washed with H2O and dried using vacuum filtration to afford the title compound (91% purity, 1.13 g, 5.19 mmol, 78% yield) as a white solid; 1H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 4.83 (p, J=7.5 Hz, 1H), 2.89-2.74 (m, 1H), 2.63-2.52 (m, 2H), 2.38-2.23 (m, 2H); M/Z: 199 [M+H]+, ESI+, RT=0.50 (S2).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-[(benzyloxy)amino]piperidine-1,2-dicarboxylate (40 g, 0.106 mol, Intermediate 1) in anhydrous EtOH (1 L) under N2 was added Pd/C (10%, 11.3 g, 10.6 mmol) and the mixture was stirred under H2 for 21 h. The reaction mixture was filtered through a pad of Celite, and the resultant filtrate was diluted with H2O (500 mL) and acidified to pH 4 using 1 M aq HCl solution. The aqueous solution was extracted with DCM (3×500 mL) and the organic extracts set aside. The aqueous layer was then basified to pH 8 using 1 M aq NaOH solution and extracted with DCM (3×500 mL). The organic extracts were combined, washed with brine (250 mL), dried over MgSO4, and concentrated in vacuo to afford the title compound (93% purity, 25.6 g, 87.3 mmol, 83% yield) as a light brown oil; 1H NMR (400 MHz, CDCl3) δ 5.01-4.59 (m, 1H), 4.21 (q, J=7.1 Hz, 2H), 3.94-3.72 (m, 1H), 3.33-3.03 (m, 2H), 2.16-1.99 (m, 2H), 1.66-1.54 (m, 2H), 1.54-1.34 (m, 11H), 1.35-1.22 (m, 3H); M/Z: 173 [M-Boc+H]+, ESI+, RT=0.67 (S2).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-aminopiperidine-1,2-dicarboxylate (93% purity, 13.3 g, 45.2 mmol, Intermediate 7), DMAP (553 mg, 4.52 mmol) and pyridine (7.34 mL, 90.7 mmol) in DCM (225 mL) at 0° C. was added benzyl chloroformate (11.3 mL, 79.2 mmol) and the mixture was stirred at r.t. for 72 h. The reaction mixture was cooled to 0° C., further portions of DMAP (553 mg, 4.52 mmol) and benzyl chloroformate (11.3 mL, 79.2 mmol) were added, and the mixture was stirred at r.t. for 2.5 h. The reaction mixture was diluted with H2O (200 mL) and extracted with DCM (3×250 mL). The combined organic extracts were dried using a phase separator, concentrated in vacuo, and purified by chromatography on silica gel (0-100% EtOAc in heptane) to afford the title compound (68% purity, 17.1 g, 28.6 mmol, 63% yield) as a yellow oil; 1H NMR (400 MHz, CDCl3) δ 7.35-7.21 (m, 5H), 5.16-4.95 (m, 3H), 4.86-4.52 (m, 1H), 4.13 (q, J=6.7 Hz, 2H), 3.99-3.69 (m, 2H), 3.20-2.95 (m, 1H), 2.13-1.95 (m, 1H), 1.91-1.69 (m, 2H), 1.37 (s, 9H), 1.20 (t, J=7.1 Hz, 3H); M/Z: 307 [M-Boc+H]+, ESI+, RT=1.25 (S2).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-{[(benzyloxy)carbonyl]amino}piperidine-1,2-dicarboxylate (68% purity, 17.1 g, 28.6 mmol) in EtOH (115 mL):THF (115 mL):H2O (115 mL) was added LiOH·H2O (1.36 g, 31.7 mmol) and the mixture was allowed to stir at r.t. for 19 h. The reaction mixture was diluted with H2O (100 mL) and EtOAc (100 mL), and the organic layer was discarded. The aqueous layer was acidified by addition of 1 M aq HCl solution and extracted with EtOAc (3×200 mL). The combined organic extracts were washed with brine, dried over MgSO4, and concentrated in vacuo to afford the title compound in quantitative yield (84% purity, 14.5 g, 32.2 mmol) as a colourless gum; 1H NMR (400 MHz, CDCl3) δ 7.45-7.31 (m, 5H), 5.27-5.04 (m, 3H), 5.02-4.71 (m, 1H), 4.09-3.80 (m, 2H), 3.30-3.09 (m, 1H), 2.23-2.05 (m, 1H), 2.05-1.75 (m, 2H), 1.71-1.51 (m, 1H), 1.47 (s, 9H); M/Z: 279 [M-Boc+H]+, ESI+, RT=0.90 (S2).
To a solution of (2R,5S)-5-{[(benzyloxy)carbonyl]amino}-1-[(tert-butoxy)carbonyl]piperidine-2-carboxylic acid (84% purity, 6.79 g, 15.1 mmol) in DMF (60 mL) was added HATU (6.88 g, 18.1 mmol) and DIPEA (3.2 mL, 18.1 mmol) and the mixture was stirred at r.t. under N2 for 30 min. The solution was then added dropwise via cannula to a solution of NH2—NH2—H2O (1.5 mL, 30.1 mmol) in DMF (30 mL) and the mixture was stirred at r.t. for 1.5 h. The reaction mixture was diluted with EtOAc (200 mL) and washed with H2O (4×50 mL). The combined organic extracts were dried over Na2SO4, concentrated in vacuo, and purified by chromatography on silica gel (0-10% MeOH in DCM) to afford the title compound in quantitative yield (79% purity, 10.2 g, 20.5 mmol) as a white solid; 1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 1H), 7.46-7.24 (m, 5H), 5.03 (s, 2H), 4.62-4.37 (m, 1H), 4.20 (s, 2H), 4.06-3.82 (m, 1H), 3.76-3.48 (m, 1H), 3.26-3.13 (m, 1H), 2.12-1.93 (m, 1H), 1.80-1.54 (m, 2H), 1.54-1.44 (m, 1H), 1.42-1.20 (m, 10H); M/Z: 293 [M-Boc+H]+, ESI+, RT=0.79 (S2).
To a solution of tert-butyl (2R,5S)-5-{[(benzyloxy)carbonyl]amino}-2-(hydrazinecarbonyl)piperidine-1-carboxylate (79% purity, 10.2 g, 20.5 mmol, Intermediate 9) in 1,4-dioxane (70 mL) was added a solution of NaHCO3 (2.58 g, 30.8 mmol) in H2O (20 mL) followed by BrCN (2.17 g, 20.5 mmol), and the mixture was stirred at r.t. for 2.5 h. The reaction mixture was diluted with H2O and the resultant precipitate was filtered under vacuum, washing with H2O, to afford the title compound in quantitative yield (84% purity, 11.0 g, 22.2 mmol) as an off-white powder; 1H NMR (400 MHz, DMSO-d6) δ 7.51-7.42 (m, 1H), 7.41-7.27 (m, 5H), 7.05-6.95 (m, 2H), 5.30 (s, 1H), 5.09-4.97 (m, 2H), 4.11-3.98 (m, 1H), 2.86-2.76 (m, 1H), 2.29-2.14 (m, 1H), 1.95-1.79 (m, 2H), 1.65-1.53 (m, 1H), 1.44-1.30 (m, 10H); M/Z: 318 [M-Boc+H]+, ESI+, RT=0.86 (S2).
To a solution of tert-butyl (2R,5S)-2-(5-amino-1,3,4-oxadiazol-2-yl)-5-{[(benzyloxy)carbonyl]amino}piperidine-1-carboxylate (84% purity, 11.0 g, 22.2 mmol) and CuBr (3 eq, 9.54 g, 66.5 mmol) in anhydrous ACN (400 mL) was added tert-butyl nitrite (90% purity, 17.6 mL, 133.0 mmol) and the mixture was stirred at r.t for 5 h. Further portions of CuBr (1.5 eq, 4.77 g, 33.3 mmol) and tert-butyl nitrite (90% purity, 8.79 mL, 66.5 mmol) were added and the mixture was stirred at r.t. for 19 h. The reaction mixture was diluted with EtOAc (250 mL) and washed with Rochelle salt (2×200 mL) and H2O (3×200 mL). The organic extracts were dried over Na2SO4, concentrated in vacuo, and purified by chromatography on silica gel (0-100% EtOAc in heptane) to afford the title compound (2.02 g, 4.03 mmol, 18% yield) as a beige solid; 1H NMR (400 MHz, DMSO-d6) δ 7.52 (d, J=6.2 Hz, 1H), 7.41-7.28 (m, 5H), 5.57-5.41 (m, 1H), 5.05 (s, 2H), 4.08-3.91 (m, 1H), 3.65-3.53 (m, 1H), 2.96-2.84 (m, 1H), 2.33-2.23 (m, 1H), 1.99-1.90 (m, 1H), 1.88-1.72 (m, 1H), 1.65-1.57 (m, 1H), 1.38 (s, 9H); M/Z: 383 [M-Boc+H]+, ESI+, RT=1.09 (S2).
To a solution of 2-(trifluoromethoxy)ethan-1-ol (13% in THF/toluene, 4.50 g, 4.43 mmol) in anhydrous THF (15 mL) at 0° C. was added NaH (60%, 322 mg, 8.06 mmol) and the resultant mixture was stirred at 0° C. for 10 min. tert-butyl (2R,5S)-5-{[(benzyloxy)carbonyl]amino}-2-(5-bromo-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate (2.02 g, 4.03 mmol) in anhydrous THF (10 mL) was added and the resultant mixture was stirred at r.t. for 2 h. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (3×100 mL). The combined organic extracts were dried over MgSO4, concentrated in vacuo, and purified by chromatography on silica gel (0-100% EtOAc in heptane) to afford the title compound (85% purity, 1.60 g, 2.56 mmol, 64% yield) as a yellow oil; 1H NMR (400 MHz, DMSO-d6) δ 7.50 (d, J=6.1 Hz, 1H), 7.43-7.26 (m, 5H), 5.46-5.29 (m, 1H), 5.04 (s, 2H), 4.80-4.58 (m, 2H), 4.57-4.41 (m, 2H), 4.43-4.26 (m, 1H), 3.73-3.51 (m, 1H), 2.96-2.80 (m, 1H), 2.32-2.16 (m, 1H), 1.96-1.73 (m, 2H), 1.69-1.49 (m, 1H), 1.37 (s, 9H); M/Z: 531 [M-Boc+H]+, ESI+, RT=3.83 (S4).
To a solution of tert-butyl (2R,5S)-5-{[(benzyloxy)carbonyl]amino}-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (85% purity, 1.60 g, 2.56 mmol) in EtOH (45 mL) under N2 was added Pd/C (10%, 3.27 g, 3.08 mmol) and the resultant mixture was stirred under H2 at r.t. for 18 h. The reaction mixture was filtered through a pad of Celite and concentrated in vacuo to afford the title compound (49% purity, 843 mg, 1.04 mmol, 41% yield) as a light brown oil; 1H NMR (400 MHz, DMSO-d6) δ 5.39-5.26 (m, 1H), 4.76-4.64 (m, 2H), 4.54-4.42 (m, 2H), 4.43-4.25 (m, 1H), 3.74-3.60 (m, 1H), 3.20-2.91 (m, 3H), 2.30-2.09 (m, 1H), 1.93-1.78 (m, 1H), 1.75-1.59 (m, 1H), 1.53-1.25 (m, 11H); M/Z: 397 [M+H]+, ESI+, RT=1.76 (S4).
To a solution of 2-amino-4-chloro-5-fluorobenzaldehyde (270 mg, 1.56 mmol) and ethyl 3,3-diethoxypropanoate (740 mg, 3.89 mmol) in toluene (3 mL) was added TsOH (27 mg, 0.156 mmol) and the mixture was stirred at 120° C. in a sealed tube for 5 h. The reaction mixture was cooled to r.t. and concentrated in vacuo. The residue was dissolved in EtOAc (10 mL), washed with satd aq NaHCO3 solution (10 ml) and H2O (10 mL), dried over MgSO4, and concentrated in vacuo. The residue was suspended in TBME/heptane (1:1) and the resultant precipitate was filtered under vacuum and dried in vacuo to afford the title compound (230 mg, 0.907 mmol, 58% yield) as an off-white powder; 1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J=2.0 Hz, 1H), 9.02 (d, J=2.0 Hz, 1H), 8.39 (d, J=7.2 Hz, 1H), 8.28 (d, J=9.7 Hz, 1H), 4.42 (q, J=7.1 Hz, 2H), 1.39 (t, J=7.1 Hz, 3H); M/Z: 252, 254 [M+H]+, ESI+, RT=1.00 (S2).
To a solution of ethyl 7-chloro-6-fluoroquinoline-3-carboxylate (230 mg, 0.907 mmol) in THF (2.5 mL) and H2O (2.5 mL) was added LiOH·H2O (46 mg, 1.09 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was concentrated in vacuo to remove the THF, and the aqueous solution was acidified to ˜ pH 3 using 1 M aq HCl solution. The resultant precipitate was collected by vacuum filtration and dried in vacuo to afford the title compound (119 mg, 0.506 mmol, 56% yield) as a pale yellow powder; 1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J=2.0 Hz, 1H), 9.01 (d, J=2.0 Hz, 1H), 8.39 (d, J=7.2 Hz, 1H), 8.28 (d, J=9.7 Hz, 1H).; M/Z: 224, 226 [M−H]−, ESI−, RT=0.74 (S2).
DABCO (190 mg, 1.70 mmol) was added to solution of 5-chloropyridine-2-carbaldehyde (2.0 g, 14.1 mmol) and methyl prop-2-enoate (5.0 mL, 55.5 mmol) under N2 and the mixture was stirred at r.t. for 12 h. The reaction mixture was concentrated in vacuo, azeotroping with toluene. The residue was dissolved in acetic anhydride (7.0 mL, 74.1 mmol) and stirred at 120° C. for 6 h. The reaction was concentrated in vacuo and purified by chromatography on silica gel (10-100% EtOAc in isohexane) to afford the title compound (620 mg, 2.93 mmol, 21% yield) as a sticky yellow oil; 1H NMR (500 MHz, DMSO-d6) δ 8.57 (dd, J=1.7, 0.9 Hz, 1H), 8.08 (d, J=1.1 Hz, 1H), 7.53 (d, J=9.6 Hz, 1H), 6.92-6.73 (m, 2H), 3.80 (s, 3H); M/Z: 210, 212 [M+H]+, ESI+, RT=0.92 (S2).
A mixture of methyl 6-chloroindolizine-2-carboxylate (0.62 g, 2.96 mmol) and LiOH·H2O (0.25 g, 5.92 mmol) in EtOH (2 mL):THF (2 mL):H2O (2 mL) was stirred at r.t. for 12 h. The reaction mixture was diluted with H2O (10 mL) and EtOAc (10 mL) and the aqueous layer was acidified using 1 M aq HCl solution. The aqueous solution was extracted with EtOAc, washed with brine, dried over MgSO4, and concentrated in vacuo to afford the title compound (380 mg, 1.90 mmol, 64% yield) as a white solid; 1H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.56 (dt, J=1.8, 0.9 Hz, 1H), 8.01 (d, J=1.0 Hz, 1H), 7.51 (d, J=9.6 Hz, 1H), 6.99-6.63 (m, 2H); M/Z: 196, 198 [M+H]+, ESI+, RT=0.74 (S2).
Example intermediate in Table 2 was synthesised according to the general route 8 as exemplified by Intermediate 12 using the corresponding starting material.
1H NMR (500 MHz, DMSO-d6) δ 12.44 (s, 1H), 8.43-8.19 (m, 1H), 8.14-7.97 (m, 1H), 7.78-7.43 (m, 1H), 6.88-6.56 (m, 2H).
tert-Butyl N-(3-chloro-2-fluoro-6-formyl-phenyl)carbamate (1.23 g, 4.45 mmol) was added to a solution of 4 M HCl in 1,4-dioxane (4.5 mL, 18.0 mmol) in anhydrous 1,4-dioxane (10 mL) and the mixture was stirred at r.t. for 3 h. The reaction mixture was concentrated in vacuo and purified by chromatography on silica gel (0-20% EtOAc in heptane) to afford the title compound (326 mg, 1.78 mmol, 40% yield); 1H NMR (400 MHz, DMSO-d6) δ 9.87 (d, J=2.0 Hz, 1H), 7.48 (dd, J=8.5, 1.6 Hz, 1H), 7.24 (s, 2H), 6.84-6.77 (m, 1H); M/Z: 174, 176 [M+H]+, ESI+, RT=0.78 (S2).
To a mixture of 2-amino-4-chloro-3-fluoro-benzaldehyde (326 mg, 1.78 mmol) and ethyl 3,3-diethoxypropanoate (850 mg, 4.47 mmol) in toluene (4 mL) was added TsOH (31 mg, 0.180 mmol) and the mixture was stirred at 120° C. in a sealed tube for 4 h. The reaction mixture was cooled to r.t. and concentrated in vacuo. The residue was dissolved in EtOAc (30 mL), and washed with satd aq NaHCO3 solution (10 mL) and H2O (10 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The residue was triturated using ACN to afford the title compound (249 mg, 0.982 mmol, 55% yield) as an off white powder; 1H NMR (500 MHz, DMSO-d6) δ 9.40 (d, J=2.0 Hz, 1H), 9.23-9.09 (m, 1H), 8.15 (dd, J=8.9, 1.4 Hz, 1H), 7.90 (dd, J=8.9, 6.8 Hz, 1H), 4.45 (q, J=7.1 Hz, 2H), 1.40 (t, J=7.1 Hz, 3H); M/Z: 254, 256 [M+H]+, ESI+, RT=3.37 (S4).
To a solution of ethyl 7-chloro-8-fluoro-quinoline-3-carboxylate (249 mg, 0.982 mmol) in THF (3 mL) and H2O (3 mL) was added LiOH·H2O (49 mg, 1.18 mmol) and the mixture was stirred at r.t. for 5 h. The reaction mixture was concentrated in vacuo and redissolved in H2O (10 mL). The aqueous solution was acidified to pH 2-3 using 4 M aq HCl solution and extracted with EtOAc (2×50 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo to afford the title compound (206 mg, 0.904 mmol, 92% yield) as an off white powder; 1H NMR (500 MHz, DMSO-d6) δ 13.81 (s, 1H), 9.39 (d, J=2.0 Hz, 1H), 9.15-9.08 (m, 1H), 8.12 (dd, J=9.0, 1.4 Hz, 1H), 7.89 (dd, J=8.9, 6.8 Hz, 1H); M/Z: 226, 228 [M+H]+, ESI+, RT=2.40 (S4).
To a solution of 7-chloroquinoline-3-carboxylic acid (3.39 g, 16.3 mmol) in anhydrous THF (90 mL) at 0° C. was added NMM (1.9 mL, 17.2 mmol) followed by isobutyl chloroformate (2.1 mL, 16.3 mmol) dropwise and the mixture was stirred at r.t. for 25 min. A solution of 1-tert-butyl 2-ethyl (2R,5S)-5-aminopiperidine-1,2-dicarboxylate (4.45 g, 16.3 mmol, Intermediate 7) in anhydrous THF (90 mL) was added and the mixture was stirred at r.t. for 48 h. T3P (50% in EtOAc, 2.4 mL, 4.08 mmol) was added and the mixture was stirred at r.t. for 1 h. The reaction mixture was diluted with H2O (100 mL) and EtOAc (100 mL), and the organic layer was separated, washed with satd aq NaHCO3 solution (100 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (92% purity, 8.09 g, 16.1 mmol, 99% yield) as a yellow viscous gel; 1H NMR (500 MHz, DMSO-d6) δ 9.25 (s, 1H), 8.84 (s, 1H), 8.65 (s, 1H), 8.17 (d, J=8.9 Hz, 2H), 7.74 (dd, J=8.7, 2.1 Hz, 1H), 4.83-4.55 (m, 1H), 4.24-4.08 (m, 2H), 3.15 (dd, J=6.4, 5.3 Hz, 1H), 2.26 (s, 1H), 1.95 (s, 1H), 1.83-1.73 (m, 1H), 1.60 (tt, J=13.3, 6.7 Hz, 1H), 1.39-1.24 (m, 11H), 1.18 (q, J=7.1 Hz, 3H); M/Z: 462, 464 [M+H]+, ESI+, RT=0.98 (S2).
To a solution of 1-tert-butyl 2-ethyl (2R,5S)-5-(7-chloroquinoline-3-amido)piperidine-1,2-dicarboxylate (92% purity, 8.09 g, 16.1 mmol) in THF (120 mL) was added 2 M aq LiOH (16 mL, 32.2 mmol) and the mixture was stirred at r.t. for 2 h. Additional 2 M aq LiOH (16 mL, 32.2 mmol) was added and the mixture was stirred at r.t. overnight. Additional 2 M aq LiOH solution (16 mL, 32.2 mmol) was added and the mixture was stirred at r.t. overnight. The reaction mixture was quenched using 2 M aq KHSO4 solution (32 mL, 64.4 mmol) and H2O (50 mL), before stirring at r.t. for 10 min and then concentrating in vacuo. EtOAc (100 mL) was added and the organic layer was separated, washed with H2O, dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in TBME (75 mL) and the resultant suspension was filtered, washing with TBME, then dried in vacuo to afford the title compound (4.19 g, 9.66 mmol, 60% yield) as a white powder; 1H NMR (500 MHz, DMSO-d6) δ 12.86 (s, 1H), 9.24 (s, 1H), 8.83 (s, 1H), 8.60 (s, 1H), 8.16 (d, J=8.8 Hz, 2H), 7.73 (dd, J=8.8, 2.0 Hz, 1H), 4.68 (s, 1H), 4.02 (q, J=7.1 Hz, 2H), 3.15 (d, J=13.6 Hz, 1H), 2.23 (s, 1H), 1.93 (d, J=26.7 Hz, 1H), 1.76 (d, J=13.1 Hz, 1H), 1.65 (s, 1H), 1.30 (d, J=51.9 Hz, 9H); M/Z: 434, 436 [M+H]+, ESI+, RT=0.82 (S2).
Intermediate compound in Table 3 was synthesised according to the general route 10 as exemplified by Intermediate 16 using the corresponding intermediates.
1H NMR (500 MHz, DMSO-d6) δ 12.82 (s, 1H), 9.25 (s, 1H), 8.84 (s, 1H), 8.73-8.53 (m, 1H), 8.19-8.10 (m, 2H), 7.74 (dd, J = 8.7, 2.1 Hz, 1H), 4.74-4.47 (m, 1H), 4.23-3.89 (m, 2H), 3.20- 3.08 (m, 1H), 2.31- 2.18 (m, 1H), 2.01-1.90 (m, 1H), 1.81-1.72 (m, 1H), 1.71-1.56 (m, 1H), 1.48-1.11 (m, 9H).
To a solution of 3,4-dichlorobenzoic acid (0.70 g, 3.67 mmol) in DMF (14.284 mL) at 0° C. was added HATU (1.68 g, 4.41 mmol) and DIPEA (1.3 mL, 7.34 mmol) and stirred for 10 min. 1-tert-butyl 2-ethyl (2S,5R)-5-aminopiperidine-1,2-dicarboxylate (1.00 g, 3.67 mmol) was added and the mixture was stirred at r.t. for 4 h. The reaction mixture was diluted with EtOAc (40 mL) and washed with H2O (3×20 mL). The organic layer was dried over MgSO4, concentrated in vacuo and purified by chromatography on silica gel (10-100% EtOAc in heptane) to afford the title compound (1.58 g, 3.50 mmol, 95% yield) as a yellow oil; 1H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.62-7.47 (m, 2H), 6.44 (d, J=94.0 Hz, 1H), 4.86 (d, J=79.2 Hz, 1H), 4.32-4.17 (m, 3H), 4.15-4.00 (m, 1H), 3.38-3.20 (m, 1H), 2.27-1.84 (m, 3H), 1.61 (s, 1H), 1.47 (s, 9H), 1.30 (t, J=7.1 Hz, 3H); M/Z: 467, 469, 471 [M+Na]+, ESI+, RT=1.06 (S2).
To a solution of 1-tert-butyl 2-ethyl (2S,5R)-5-(3,4-dichlorobenzamido)piperidine-1,2-dicarboxylate (1.58 g, 3.50 mmol) in EtOH (10 mL) and THF (10 mL) was added 2 M LiOH (1.8 mL, 3.50 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was acidified to pH 2 using 1 M aq HCl solution and extracted with EtOAc (2×50 mL). The combined organic extracts were dried over MgSO4 and concentrated in vacuo to afford the title compound (92% purity, 1.55 g, 3.42 mmol, 97% yield) as a white solid; 1H NMR (400 MHz, CDCl3) δ 8.39-7.65 (m, 2H), 7.67-7.40 (m, 2H), 6.76-6.35 (m, 1H), 5.08-4.76 (m, 1H), 4.36-4.22 (m, 1H), 4.12-4.01 (m, 1H), 3.38-3.19 (m, 1H), 2.25-2.09 (m, 2H), 1.94 (ddq, J=14.3, 10.2, 5.1, 3.9 Hz, 1H), 1.69 (s, 1H), 1.45 (s, 9H); M/Z: 439, 441, 443 [M+Na]+, ESI+, RT=0.90 (S2).
To a solution of 6-(trifluoromethyl)quinoline-2-carboxylic acid (47 mg, 0.194 mmol) in THF (0.5 mL) was added T3P (50% in EtOAc, 0.14 mL, 0.233 mmol) and DIPEA (41 μL, 0.233 mmol) and the mixture was stirred at r.t. for 10 min. tert-butyl (2R,5S)-5-amino-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (49% purity, 120 mg, 0.148 mmol, Intermediate 10) in THF (1.5 mL) was added and the mixture was stirred at r.t. for 4 h. The reaction mixture was diluted with satd aq NaHCO3 solution (2 mL) and extracted with DCM (2×5 mL). The combined organic extracts were dried using a phase separator and concentrated in vacuo to afford the title compound, in what was assumed to be quantitative yield (67% purity, 179 mg, 0.194 mmol), as an orange gum. The material was taken into the next step crude, without further purification.
To a solution of tert-butyl (2R,5S)-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}-5-[6-(trifluoromethyl)quinoline-2-amido]piperidine-1-carboxylate (67% purity, 179 mg, 0.194 mmol, Example 1) in DCM (5 mL) was added ZnBr2 (131 mg, 0.580 mmol) and the mixture was stirred at r.t. for 16 h. A further portion of ZnBr2 was added and stirred at r.t. for 3 h. The reaction mixture was diluted with satd aq NaHCO3 solution (2 mL) and extracted with DCM:IPA (4:1, 2×2 mL). The combined organic extracts were dried using a phase separator, concentrated in vacuo, and purified by chromatography on silica gel (0-100% EtOAc in heptane, followed by 0-20% MeOH in EtOAc). The residue was purified by prep. HPLC (Method 6) to afford the title compound (15.3 mg, 0.0286 mmol, 15% yield) as a white powder; 1H NMR (400 MHz, DMSO-d6) δ 8.80 (s, 1H), 8.78 (s, 1H), 8.65 (s, 1H), 8.37 (d, J=8.9 Hz, 1H), 8.29 (d, J=8.5 Hz, 1H), 8.13 (dd, J=9.0, 2.1 Hz, 1H), 4.74-4.66 (m, 2H), 4.53-4.45 (m, 2H), 4.05-3.92 (m, 1H), 3.91-3.82 (m, 1H), 3.15-3.06 (m, 1H), 2.97-2.86 (m, 1H), 2.77-2.65 (m, 1H), 2.09-1.98 (m, 21H), 1.87-1.67 (in, 21H); M/Z: 520 [M+H]+, ESI+, RT=2.46 (S4).
Example compounds in Table 4 were synthesised according to the general route 12 as exemplified by Example 2 using the corresponding intermediates. The corresponding boc protected intermediates of the numbered examples are also examples of the invention.
1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 2.2 Hz, 1H), 8.86 (d, J = 2.1 Hz, 1H), 8.63 (d, J = 7.7 Hz, 1H), 8.17 (d, J = 9.0 Hz, 2H), 7.74 (dd, J = 8.7, 2.2 Hz, 1H), 4.75- 4.65 (m, 2H), 4.53- 4.45 (m, 2H), 4.00-3.86 (m, 1H), 3.86-3.77 (m,
1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, J = 7.8 Hz, 1H), 7.28-7.22 (m, 2H), 7.02 (dd, J = 8.1, 2.1 Hz, 1H), 6.96 (d, J = 1.8 Hz, 1H), 4.93 (d, J = 1.4 Hz, 2H), 4.74- 4.63 (m, 2H), 4.51-4.42 (m, 2H), 3.81-3.66 (m, 2H), 3.08-2.96 (m, 1H),
1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.71 (d, J = 8.6 Hz, 1H), 8.61 (s, 1H), 8.41 (d, J = 2.1 Hz, 1H), 8.27 (d, J = 9.0 Hz, 1H), 7.91 (dd, J = 8.8, 2.1 Hz, 1H), 4.73-4.66 (m, 2H), 4.52- 4.44 (m, 2H), 4.05- 3.91 (m, 1H), 3.90-3.80
1H NMR (500 MHz, DMSO-d6) δ 9.73 (d, J = 0.7 Hz, 1H), 8.84 (d, J = 8.4 Hz, 1H), 8.43 (d, J = 2.4 Hz, 1H), 8.21 (d, J = 9.0 Hz, 1H), 8.15 (dd, J = 9.0, 2.4 Hz, 1H), 4.73- 4.66 (m, 2H), 4.52- 4.45 (m, 2H), 4.02-3.90 (m, 1H), 3.88-3.80 (m,
To a solution of 6-chloroquinoline-3-carboxylic acid (63 mg, 0.303 mmol) in anhydrous DMF (3 mL) was added HATU (138 mg, 0.364 mmol) followed by DIPEA (106 μL, 0.607 mmol) and stirred at r.t. for 10 min. tert-butyl (2R,5S)-5-amino-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (120 mg, 0.303 mmol, Intermediate 10) was added and the mixture was stirred at r.t. for 19 h. A further portion of HATU (35 mg, 0.091 mg) was added and the mixture was stirred at r.t. for 1 h. The reaction mixture was partitioned between EtOAc (10 mL) and 1 M aq HCl solution (10 mL). The organic layer was isolated, washed with satd aq NaHCO3 (10 mL) and brine (10 mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel (20-100% EtOAc in heptane) to afford the title compound (94% purity, 100 mg, 0.160 mmol, 53% yield) as an off-white powder; 1H NMR (400 MHz, DMSO-d6) δ 9.28-9.20 (m, 1H), 8.82-8.75 (m, 1H), 8.68 (d, J=6.2 Hz, 1H), 8.29-8.21 (m, 1H), 8.15-8.08 (m, 1H), 7.87 (dd, J=9.0, 2.4 Hz, 1H), 5.50-5.38 (m, 1H), 4.75-4.62 (m, 2H), 4.55-4.42 (m, 2H), 4.26-4.13 (m, 1H), 4.12-4.05 (m, 1H), 3.03 (dd, J=14.0, 2.4 Hz, 1H), 2.07-1.89 (m, 3H), 1.86-1.76 (m, 1H), 1.23 (s, 9H); M/Z: 486, 488 [M-Boc+H]+, ESI+, RT=1.01 (S2).
To a solution of tert-butyl (2R,5S)-5-(6-chloroquinoline-3-amido)-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (94% purity, 98 mg, 0.157 mmol, Example 7) in DCM (4 mL) was added ZnBr2 (106 mg, 0.472 mmol) and the mixture was stirred under N2 at r.t. for 20 h. The reaction mixture was diluted with H2O (3 mL) and extracted with DCM/IPA (9:1, 3×3 mL). The combined organics were dried using a phase separator, concentrated in vacuo and purified by prep. HPLC (Method 2). The product containing fractions were combined, basified to pH 9 using satd NaHCO3 solution, and extracted with EtOAc (3×25 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo to afford the title compound (17 mg, 0.0347 mmol, 22% yield) as a white powder; 1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J=2.2 Hz, 1H), 8.78 (d, J=2.0 Hz, 1H), 8.64 (d, J=7.8 Hz, 1H), 8.24 (d, J=2.4 Hz, 1H), 8.14-8.07 (m, 1H), 7.87 (dd, J=9.0, 2.4 Hz, 1H), 4.73-4.64 (m, 2H), 4.52-4.43 (m, 2H), 3.98-3.87 (m, 1H), 3.85-3.77 (m, 1H), 3.18-3.10 (m, 1H), 2.90-2.82 (m, 1H), 2.61-2.53 (m, 1H), 2.10-1.96 (m, 2H), 1.79-1.55 (m, 2H); M/Z: 486, 488 [M+H]+, ESI+, RT=1.98 (S4).
Example compounds in Table 5 were synthesised according to the general route 13 as exemplified by Example 8 using the corresponding intermediates. The corresponding boc protected intermediates of the numbered examples are also examples of the invention.
1H NMR Data
1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 8.1 Hz, 1H), 7.88 (d, J = 2.2 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 0.9 Hz, 1H), 7.49 (dd, J = 8.8, 2.2 Hz, 1H), 4.73- 4.64 (m, 2H), 4.52- 4.43 (m, 2H), 3.94-3.82 (m, 1H), 3.82-3.73 (m, 1H), 3.12-3.01 (m, 1H),
1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 2.1 Hz, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.67 (d, J = 7.7 Hz, 1H), 8.37 (d, J = 7.2 Hz, 1H), 8.17 (d, J = 9.6 Hz, 1H), 4.75-4.66 (m, 2H), 4.52-4.41 (m, 2H), 3.99-3.87 (m, 1H), 3.86-3.74 (m, 1H), 3.14
1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 7.4 Hz, 1H), 8.24 (d, J = 8.3 Hz, 1H), 8.00-7.93 (m, 1H), 7.08 (dd, J = 7.4, 2.4 Hz, 1H), 4.73- 4.66 (m, 2H), 4.51-4.46 (m, 2H), 3.95-3.86 (m, 1H), 3.83-3.76 (m, 1H), 3.09-3.00 (m, 1H), 2.89- 2.81 (m, 1H), 2.64-
1H NMR (400 MHz, DMSO-d6) δ 8.67 (d, J = 2.4 Hz, 1H), 8.31 (d, J = 7.7 Hz, 1H), 8.22 (dd, J = 8.7, 2.4 Hz, 1H), 7.07 (d, J = 8.6 Hz, 1H), 5.07 (q, J = 9.1 Hz, 2H), 4.75- 4.64 (m, 2H), 4.53- 4.44 (m, 2H), 3.92-3.75 (m, 2H), 3.14-3.05 (m, 1H), 2.87-2.79 (m, 1H), 2.54-2.52 (m, 1H), 2.05-
1H NMR (500 MHz, CDCl3) δ 8.47 (d, J = 8.5 Hz, 1H), 8.42 (d, J = 1.7 Hz, 1H), 8.31 (d, J = 8.8 Hz, 1H), 8.16 (dd, J = 8.8, 1.9 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 6.75 (d, J = 7.2 Hz, 1H), 4.75- 4.70 (m, 2H), 4.40-4.33 (m, 2H), 4.32-4.24 (m, 1H), 4.12 (dd, J = 6.4, 4.2 Hz, 1H), 3.41 (dd, J =
1H NMR (500 MHz, CDCl3) δ 8.68-8.59 (m, 2H), 8.05-7.96 (m, 1H), 7.53 (s, 1H), 6.83 (s, 1H), 4.74-4.68 (m, 2H), 4.37-4.31 (m, 2H), 4.21- 4.11 (m, 1H), 4.03 (dd, J = 8.7, 3.2 Hz, 1H), 3.41 (dd, J = 12.0, 3.6 Hz, 1H), 2.72 (dd, J = 12.1,
1H NMR (400 MHz, CDCl3) δ 8.70 (d, J = 2.3 Hz, 1H), 8.25 (dd, J = 8.5, 2.5 Hz, 1H), 7.08 (d, J = 8.5 Hz, 1H), 6.59 (d, J = 7.6 Hz, 1H), 4.81- 4.63 (m, 2H), 4.45-4.29 (m, 2H), 4.20 (dt, J = 6.8, 3.6 Hz, 1H), 4.10 (t, J = 5.2 Hz, 1H), 3.35
1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 2.0 Hz, 1H), 7.62 (dd, J = 8.4, 2.0 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 6.49 (s, 1H), 4.75-4.67 (m, 2H), 4.38-4.32 (m, 2H), 4.17 (s, 1H), 4.11-4.05 (m, 1H), 3.35 (dd, J = 11.8, 3.2 Hz, 1H), 2.72 (dd, J = 12.1, 6.7 Hz, 1H), 2.22-
1H NMR (400 MHz, CDCl3) δ 7.76-7.71 (m, 2H), 7.45-7.39 (m, 2H), 6.46 (d, J = 7.4 Hz, 1H), 4.74-4.67 (m, 2H), 4.37- 4.32 (m, 2H), 4.23- 4.14 (m, 1H), 4.07 (dd, J = 6.9, 4.0 Hz, 1H), 3.37 (dd, J = 12.1, 3.3 Hz, 1H), 2.71 (dd, J = 12.0, 6.9 Hz, 1H), 2.22-1.95
1H NMR (500 MHz, DMSO-d6) δ 9.34 (d, J = 2.0 Hz, 1H), 9.00-8.87 (m, 1H), 8.70 (d, J = 7.8 Hz, 1H), 8.10-7.97 (m, 1H), 7.85 (dd, J = 8.8, 6.8 Hz, 1H), 4.77-4.65 (m, 2H), 4.54-4.45 (m, 2H), 4.00-3.89 (m, 1H), 3.86-3.78 (m, 1H), 3.20-3.12 (m, 1H), 2.93- 2.84 (m, 1H), 2.61-2.54 (m, 1H), 2.12-2.00 (m,
1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 7.4 Hz, 1H), 7.78-7.73 (m, 1H), 7.34 (d, J = 1.9 Hz, 1H), 6.55 (s, 1H), 6.51 (dd, J = 7.4, 2.1 Hz, 1H), 6.30 (d, J = 7.5 Hz, 1H), 4.74-4.68 (m, 2H), 4.37- 4.31 (m, 2H), 4.19 (tt, J = 7.7, 4.1 Hz, 1H), 4.06 (dd, J = 7.5, 3.7 Hz, 1H), 3.39 (dd, J = 11.9, 3.2 Hz, 1H), 2.70 (dd, J =
1H NMR (400 MHz, CDCl3) δ 7.97-7.91 (m, 1H), 7.75 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 9.5 Hz, 1H), 6.71-6.62 (m, 2H), 6.31 (d, J = 7.2 Hz, 1H), 4.74-4.67 (m, 2H), 4.38- 4.31 (m, 2H), 4.19 (tt, J = 7.5, 4.1 Hz, 1H), 4.06 (dd, J = 7.5, 3.7 Hz, 1H), 3.39 (dd, J = 12.0, 3.3 Hz, 1H), 2.70 (dd, J = 12.1, 7.4 Hz, 1H),
1H NMR (400 MHz, DMSO-d6) δ 8.46 (d, J = 8.0 Hz, 1H), 8.08 (s, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.8, 1.6 Hz, 1H), 7.25 (s, 1H), 4.75- 4.66 (m, 2H), 4.52-4.45 (m, 2H), 4.03 (s, 3H), 3.92-3.75 (m, 2H), 3.16- 3.06 (m, 1H), 2.90- 2.80 (m, 1H), 2.07-1.98
1H NMR (500 MHz, CDCl3) δ 7.77 (t, J = 1.8 Hz, 1H), 7.66 (dt, J = 7.7, 1.3 Hz, 1H), 7.48 (ddd, J = 8.0, 2.1, 1.0 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 6.47 (s, 1H), 4.74- 4.68 (m, 2H), 4.37-4.32 (m, 2H), 4.23-4.14 (m, 1H), 4.08 (dd, J = 6.8, 4.1 Hz, 1H), 3.36 (dd, J = 12.0, 3.2 Hz, 1H), 2.71 (dd, J = 12.1, 6.9 Hz, 1H), 2.22-1.96 (m, 3H),
1H NMR (500 MHz, CDCl3) δ 7.37 (s, 2H), 7.14 (s, 1H), 6.37 (d, J = 6.7 Hz, 1H), 4.74-4.68 (m, 2H), 4.38-4.32 (m, 2H), 4.18 (dp, J = 11.7, 4.0 Hz, 1H), 4.05 (dd, J = 7.5, 3.8 Hz, 1H), 3.38 (dd, J = 11.9, 3.2 Hz, 1H), 2.69 (dd, J = 12.0, 7.4 Hz, 1H), 2.37 (s, 6H), 2.21-2.07 (m, 2H), 1.98 (ddt, J = 15.7, 7.7, 3.5
1H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 7.49 (dd, J = 7.8, 1.7 Hz, 1H), 7.19 (d, J = 7.8 Hz, 1H), 6.40 (d, J = 7.1 Hz, 1H), 4.73-4.69 (m, 2H), 4.37-4.32 (m, 2H), 4.18 (ddq, J = 11.3, 7.6, 3.5 Hz, 1H), 4.06 (dd, J = 7.6, 3.8 Hz, 1H), 3.39 (dd, J = 12.1, 3.3 Hz, 1H), 2.69 (dd, J = 12.1,
1H NMR (500 MHz, CDCl3) δ 7.23 (s, 1H), 6.11 (d, J = 6.7 Hz, 1H), 4.73-4.67 (m, 2H), 4.36- 4.31 (m, 2H), 4.11 (dp, J = 11.5, 3.8 Hz, 1H), 4.03 (dd, J = 7.5, 3.9 Hz, 1H), 3.35 (dd, J = 12.0, 3.3 Hz, 1H), 2.66 (dd, J = 12.1, 7.4 Hz, 1H), 2.36 (s, 3H), 2.19-2.05 (m, 5H), 1.96 (ddt, J = 16.9, 8.2, 3.8 Hz, 1H), 1.71-
1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.2 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 6.42 (d, J = 6.6 Hz, 1H), 4.72-4.69 (m, 2H), 4.36-4.33 (m, 2H), 4.22-4.14 (m, 1H), 4.05 (dd, J = 7.4, 3.9 Hz, 1H), 3.38 (dd, J = 12.0, 3.3 Hz, 1H), 2.69 (dd, J = 12.1, 7.3 Hz, 1H), 2.40
To a solution of 4-(trifluoromethoxy)benzoic acid (44 mg, 0.182 mmol) in anhydrous THF (4 mL) was added DIPEA (95 μL, 0.545 mmol), HATU (83 mg, 0.218 mmol) and tert-butyl (2R,5S)-5-amino-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (90% purity, 80 mg, 0.182 mmol, Intermediate 10) and the mixture was stirred at r.t. for 16 h. The reaction mixture was diluted with satd aq NaHCO3 solution (5 mL) and extracted with EtOAc (2×5 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo to afford the title compound (65% purity, 160 mg, 0.178 mmol, 98% yield) as a yellow oil; M/Z: 485 [M-Boc+H]+, ESI+, RT=1.04 (S2).
To a solution of tert-butyl (2R,5S)-5-[4-(trifluoromethoxy)benzamido]-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (65% purity, 160 mg, 0.178 mmol, Example 28) in anhydrous DCM (5 mL) was added ZnBr2 (109 mg, 0.484 mmol) and the mixture was stirred vigorously at r.t. for 16 h. The reaction mixture was diluted with DCM/IPA (2:1, 10 mL) and H2O (5 mL) and the organic layer was separated, dried over Na2SO4 and concentrated in vacuo. The residue was purified by prep. HPLC (Method 3), followed by prep. HPLC (Method 1). The relevant fractions were diluted with satd aq NaHCO3 solution (5 mL) and extracted with EtOAc (2×25 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in ACN/H2O (1:1, 2 mL) and freeze dried to afford the title compound (6.0 mg, 0.0120 mmol, 7.4% yield) as a white powder; 1H NMR (500 MHz, MeOD) δ 8.01-7.85 (m, 2H), 7.38 (d, J=8.1 Hz, 2H), 4.76-4.70 (m, 2H), 4.66-4.54 (m, 1H), 4.48-4.40 (m, 2H), 4.12-4.01 (m, 1H), 3.97-3.87 (m, 1H), 3.34-3.33 (m, 1H), 2.73-2.62 (m, 1H), 2.24-2.14 (m, 2H), 1.97-1.83 (m, 1H), 1.77-1.63 (m, 1H); M/Z: 485 [M+H]+, ESI+, RT=2.15 (S4).
Example compounds in Table 6 were synthesised according to the general route 14 as exemplified by Example 29 using the corresponding intermediates. The corresponding boc protected intermediates of the numbered examples are also examples of the invention.
1H NMR Data
1H NMR (500 MHz, MeOD) δ 7.77-7.66 (m, 2H), 7.31 (d, J = 8.4 Hz, 1H), 4.74-4.71 (m, 2H), 4.60-4.58 (m, 1H), 4.45- 4.42 (m, 2H), 4.09- 4.00 (m, 1H), 3.95-3.89 (m, 1H), 3.31-3.28 (m, 1H), 2.69-2.62 (m, 1H), 2.23-2.16 (m, 2H), 1.95-
1H NMR (500 MHz, MeOD) δ 7.76 (d, J = 1.9 Hz, 1H), 7.66-7.60 (m, 1H), 7.45 (d, J = 8.3 Hz, 1H), 4.75-4.70 (m, 2H), 4.65-4.54 (m, 1H), 4.48- 4.40 (m, 2H), 4.11- 4.00 (m, 1H), 3.95-3.87 (m, 1H), 3.31-3.26 (m, 1H), 2.70-2.62 (m, 1H), 2.23-2.14 (m, 2H), 1.95-
1H NMR (400 MHz, MeOD) δ 7.65 (d, J = 7.6 Hz, 2H), 4.76-4.73 (m, 2H), 4.68-4.51 (m, 1H), 4.48-4.43 (m, 2H), 4.11- 4.00 (m, 1H), 3.98- 3.89 (m, 1H), 3.32-3.27 (m, 1H), 2.71-2.63 (m, 1H), 2.26-2.16 (m, 2H), 1.96-1.84 (m, 1H), 1.76- 1.64 (m, 1H).
1H NMR (500 MHz, MeOD) δ 7.85-7.75 (m, 3H), 4.76-4.70 (m, 2H), 4.64-4.52 (m, 1H), 4.47- 4.41 (m, 2H), 4.12- 4.02 (m, 1H), 3.98-3.88 (m, 1H), 3.37-3.33 (m, 1H), 2.75-2.61 (m, 1H), 2.26-2.15 (m, 2H), 1.97- 1.83 (m, 1H), 1.77- 1.64 (m, 1H).
1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 2.1 Hz, 1H), 7.93 (dd, J = 8.6, 2.1 Hz, 1H), 7.68 (dd, J = 8.6, 1.4 Hz, 1H), 4.71-4.66 (m, 2H), 4.50- 4.45 (m, 2H), 3.88- 3.76 (m, 2H), 3.08 (d, J = 11.5 Hz, 1H), 2.84 (s, 1H), 2.00 (d, J = 10.4
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 6.5 Hz, 1H), 8.01 (s, 1H), 7.30 (d, J = 9.2 Hz, 1H), 6.54 (s, 1H), 4.74-4.68 (m, 2H), 4.35 (dd, J = 5.3, 3.4 Hz, 2H), 4.25- 4.16 (m, 1H), 4.13-4.07 (m, 1H), 3.37 (dd, J = 12.1, 3.0 Hz, 1H), 2.74 (dd, J = 12.0, 6.7 Hz,
1H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H), 7.79-7.74 (m, 2H), 6.60 (d, J = 6.6 Hz, 1H), 4.75- 4.67 (m, 2H), 4.40- 4.30 (m, 2H), 4.26-4.15 (m, 1H), 4.10 (dd, J = 6.1, 4.4 Hz, 1H), 3.35 (dd, J = 12.1, 3.2 Hz, 1H), 2.74 (dd, J = 12.1, 6.4 Hz, 1H), 2.20-1.98 (m, 3H), 1.84-1.69 (m,
1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 1.9 Hz, 1H), 7.92 (dd, J = 8.3, 2.0 Hz, 1H), 7.62 (d, J = 8.3 Hz, 1H), 6.57 (d, J = 7.5 Hz, 1H), 4.80- 4.69 (m, 2H), 4.42-4.34 (m, 2H), 4.29-4.17 (m, 1H), 4.12 (dd, J = 6.4, 4.1 Hz, 1H), 3.39 (dd, J = 12.0, 3.2 Hz, 1H), 2.76
1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 8.28 (s, 1H), 8.07-8.01 (m, 1H), 4.74-4.67 (m, 2H), 4.37-4.30 (m, 2H), 4.21-4.09 (m, 1H), 4.05 (dd, J = 8.3, 3.3 Hz, 1H), 3.40 (dd, J = 12.1, 3.5 Hz, 1H), 2.73 (dd, J = 12.1, 8.1 Hz, 1H), 2.24- 2.15 (m, 2H), 2.03-1.90
1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 7.7 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.84 (s, 1H), 4.71 (s, 2H), 4.35 (d, J = 2.8 Hz, 2H), 4.11 (s, 1H), 4.02 (d, J = 8.9 Hz, 1H), 3.40 (d, J = 13.5 Hz, 1H), 2.78-2.69 (m, 1H), 2.20 (d, J = 9.6 Hz, 2H), 1.95 (d, J = 9.4 Hz, 1H), 1.70 (d, J = 9.7 Hz, 2H).
1H NMR (500 MHz, MeOD) δ 7.96-7.89 (m, 1H), 7.85 (dd, J = 8.4, 2.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 4.75-4.70 (m, 2H), 4.61-4.58 (m, 1H), 4.46-4.41 (m, 2H), 4.11-4.01 (m, 1H), 3.95- 3.88 (m, 1H), 3.31- 3.29 (m, 1H), 2.71-2.62 (m, 1H), 2.24-2.14 (m,
To a solution of ethyl 6-(trifluoromethyl)-1H-indole-2-carboxylate (100 mg, 0.389 mmol) in anhydrous DMF (4 mL) at 0° C. was added KOH powder (128 mg, 1.94 mmol), followed by MeI (48 μL, 0.778 mmol) and the mixture was stirred at r.t. for 20 h. The reaction mixture was partitioned between H2O (25 mL) and DCM (25 mL) and the layers were separated. The organic layer was discarded and the aqueous layer was acidified to pH 2/3 at 0° C. by slow dropwise addition of 1 M aq HCl solution. The aqueous layer was then extracted with EtOAc (2×20 mL) and the combined organics were washed with H2O (20 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (85 mg, 0.343 mmol, 88% yield) as an orange solid; 1H NMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.89 (d, J=8.4 Hz, 1H), 7.39 (dd, J=8.4, 1.3 Hz, 1H), 7.32 (d, J=0.7 Hz, 1H), 4.11 (s, 3H); M/Z: 242 [M−H]−, ESI−, RT=1.20 (S3).
To a solution of 1-methyl-6-(trifluoromethyl)indole-2-carboxylic acid (85 mg, 0.343 mmol) in anhydrous 2-MeTHF (2 mL) at 0° C. was added isobutyl chloroformate (42 μL, 0.325 mmol) and NMM (38 μL, 0.343 mmol) and the mixture was stirred for 15 min. A solution of tert-butyl (2R,5S)-5-amino-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (141 mg, 0.343 mmol, Intermediate 10) in anhydrous 2-MeTHF (2 mL) was added dropwise and the mixture was stirred at r.t. for 3 h. The reaction mixture was cooled to 0° C. and quenched with H2O (5 mL). The layers were separated and the aqueous layer was further extracted with EtOAc (5 mL). The combined organic extracts were washed with satd aq NaHCO3 solution and brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel (30-100% EtOAc in heptane) to afford the title compound (38 mg, 0.0581 mmol, 17% yield) as a colourless oil; 1H NMR (400 MHz, CDCl3) δ 7.76-7.65 (m, 2H), 7.38 (d, J=8.1 Hz, 1H), 6.86 (s, 1H), 6.76-6.33 (m, 1H), 5.73-5.23 (m, 1H), 4.75-4.66 (m, 2H), 4.38-4.32 (m, 2H), 4.31-4.26 (m, 1H), 4.26-4.19 (m, 1H), 4.10 (s, 3H), 3.38-2.94 (m, 1H), 2.29-2.18 (m, 1H), 2.18-1.99 (m, 3H), 1.54-1.40 (m, 9H); M/Z: 644 [M+Na]+, ESI+, RT=1.43 (S1).
To a solution of tert-butyl (2R,5S)-5-[[1-methyl-6-(trifluoromethyl)indole-2-carbonyl]amino]-2-[5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate (38 mg, 0.0581 mmol, Example 41) in anhydrous DCM (1 mL) was added ZnBr2 (52 mg, 0.232 mmol) and the mixture was stirred at r.t. for 6 h. The reaction mixture was diluted with satd aq NaHCO3 solution and extracted twice with DCM:IPA (4:1). The combined organic extracts were concentrated in vacuo and purified by prep. HPLC (Method 2). The relevant fractions were combined, basified to pH 9 with satd aq NaHCO3 solution and extracted with EtOAc (2×10 mL). The combined organics were washed with brine (10 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (6.0 mg, 0.0115 mmol, 20% yield) as a white powder; 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J=8.0 Hz, 1H), 7.96 (s, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.38 (dd, J=8.4, 1.3 Hz, 1H), 7.19 (s, 1H), 4.73-4.64 (m, 2H), 4.53-4.41 (m, 2H), 4.05 (s, 3H), 3.93-3.82 (m, 1H), 3.82-3.74 (m, 1H), 3.14-3.06 (m, 1H), 2.89-2.79 (m, 1H), 2.53-2.52 (m, 1H), 2.05-1.96 (m, 2H), 1.76-1.54 (m, 2H); M/Z: 522 [M+H]+, ESI+, RT=2.52 (S4).
To a solution of tert-butyl (2R,5S)-5-amino-2-[5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate (130 mg, 0.295 mmol, Intermediate 10), 3-chloro-4-methyl-benzoic acid (50 mg, 0.295 mmol) and NMI (75 mg, 0.915 mmol) in anhydrous ACN (3 mL) was added TCFH (91 mg, 0.325 mmol) and the mixture was stirred at r.t. for 2 h. The reaction mixture was diluted with H2O (15 mL) and the aqueous layer was extracted with EtOAc (2×15 mL) The combined organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was purified by chromatography on silica gel (5-100% EtOAc in heptane) to afford the title compound (91% purity, 75 mg, 0.124 mmol, 42% yield) as a colourless oil; M/Z: 549, 551 [M+H]+, ESI+, RT=1.02 (S2).
To a stirred solution of tert-butyl (2R,5S)-5-[(3-chloro-4-methyl-benzoyl)amino]-2-[5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate (75 mg, 0.124 mmol, Example 43) in anhydrous DCM (4 mL) was added ZnBr2 (84 mg, 0.373 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was diluted with H2O (15 mL) and the aqueous layer was extracted with DCM (3×15 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo, and purified by prep. HPLC (Method 3) to afford the title compound (9.2 mg, 0.0203 mmol, 16% yield) as a white solid; 1H NMR (400 MHz, DMSO-d6) δ 8.27 (d, J=7.8 Hz, 1H), 7.90 (d, J=1.7 Hz, 1H), 7.73 (dd, J=7.9, 1.7 Hz, 1H), 7.44 (d, J=8.2 Hz, 1H), 4.71-4.66 (m, 2H), 4.50-4.45 (m, 2H), 3.90-3.72 (m, 2H), 3.07 (d, J=12.3 Hz, 1H), 2.85-2.77 (m, 1H), 2.37 (s, 3H), 2.04-1.95 (m, 2H), 1.74-1.51 (m, 2H); M/Z: 449, 451 [M+H]+, ESI+, RT=1.97 (S4).
A solution of (2R,5S)-1-tert-butoxycarbonyl-5-[(7-chloroquinoline-3-carbonyl)amino]piperidine-2-carboxylic acid (350 mg, 0.807 mmol, Intermediate 16) in anhydrous 2-MeTHF (9 mL) was cooled to 0° C. and treated with isobutyl chloroformate (99 μL, 0.766 mmol) and NMM (89 μL, 0.807 mmol). The mixture was stirred for 15 min before 4-chlorobenzohydrazide (138 mg, 0.807 mmol) was added and stirred at r.t. for 1 h. The reaction mixture was cooled to 0° C. and then quenched with H2O (1 mL). The solution was partitioned between EtOAc (20 mL) and H2O (20 mL) and the layers were separated. The aqueous layer was extracted again with EtOAc (10 mL). The combined organic extracts were washed with satd aq NaHCO3 solution (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (450 mg, 0.729 mmol, 90% yield) as an off-white powder; 1H NMR (400 MHz, CDCl3) δ 9.24 (d, J=2.1 Hz, 1H), 8.88-8.72 (m, 2H), 8.55 (d, J=1.8 Hz, 1H), 8.14 (d, J=1.7 Hz, 1H), 7.83 (d, J=8.7 Hz, 1H), 7.79-7.73 (m, 2H), 7.58 (dd, J=8.7, 2.0 Hz, 1H), 7.46-7.39 (m, 2H), 4.98 (s, 1H), 4.43-4.25 (m, 2H), 3.52-3.37 (m, 1H), 2.35-2.18 (m, 1H), 2.12-1.99 (m, 2H), 1.99-1.86 (m, 2H), 1.58-1.34 (m, 9H); M/Z: 586, 588, 590 [M+H]+, ESI+, RT=1.20 (S1).
A solution of tert-butyl (2R,5S)-2-[[(4-chlorobenzoyl)amino]carbamoyl]-5-[(7-chloroquinoline-3-carbonyl)amino]piperidine-1-carboxylate (450 mg, 0.729 mmol), TsCl (417 mg, 2.19 mmol) and K2C03 (604 mg, 4.37 mmol) in anhydrous ACN (8 mL) was stirred at 80° C. for 1 h. The reaction mixture was cooled to r.t. and quenched with H2O (10 mL). The aqueous layer was extracted with EtOAc (2×20 mL) and the combined organic extracts were washed with satd aq NaHCO3 solution (3×20 mL) and brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel (40-100% EtOAc in heptane) to afford the title compound (327 mg, 0.546 mmol, 75% yield) as an off-white solid; 1H NMR (400 MHz, CDCl3) δ 9.26 (d, J=2.2 Hz, 1H), 8.57 (d, J=1.7 Hz, 1H), 8.18 (d, J=1.8 Hz, 1H), 8.02-7.95 (m, 2H), 7.87 (d, J=8.7 Hz, 1H), 7.60 (dd, J=8.7, 2.0 Hz, 1H), 7.54-7.46 (m, 2H), 6.96-6.42 (m, 1H), 5.96-5.51 (m, 1H), 4.42-4.34 (m, 1H), 4.34-4.24 (m, 1H), 3.44-3.23 (m, 1H), 2.36 (d, J=13.2 Hz, 1H), 2.31-2.16 (m, 2H), 2.15-2.05 (m, 1H), 1.51 (s, 9H); M/Z: 568 [M+H]+, ESI+, RT=1.38 (S1).
To a solution of tert-butyl (2R,5S)-2-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-5-[(7-chloroquinoline-3-carbonyl)amino]piperidine-1-carboxylate (327 mg, 0.546 mmol, Example 45) in DCM (5 mL) was added TFA (1 mL) and the mixture was stirred at r.t. for 1 h. The reaction mixture was then quenched dropwise onto satd aq NaHCO3 solution (10 mL) at 0° C. The layers were separated and the aqueous layer was extracted with DCM (10 mL). The combined organic layers were washed with satd aq NaHCO3 solution (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by prep.
HPLC (Method 5) to afford the title compound (109 mg, 0.233 mmol, 43% yield) as an off-white powder; 1H NMR (400 MHz, CDCl3) δ 9.31 (d, J=1.9 Hz, 1H), 8.63 (s, 1H), 8.19 (s, 1H), 8.08-7.98 (m, 2H), 7.90 (d, J=8.7 Hz, 1H), 7.62 (dd, J=8.7, 1.8 Hz, 1H), 7.57-7.47 (m, 2H), 6.74 (d, J=7.3 Hz, 1H), 4.40-4.26 (m, 2H), 3.52 (dd, J=12.0, 3.0 Hz, 1H), 2.86 (dd, J=12.0, 6.9 Hz, 1H), 2.39-2.28 (m, 1H), 2.28-2.11 (m, 2H), 1.95-1.83 (m, 1H); M/Z: 468, 470, 472 [M+H]+, ESI+, RT=2.10 (S4).
A solution of (2R,5S)-1-tert-butoxycarbonyl-5-[(7-chloroquinoline-3-carbonyl)amino]piperidine-2-carboxylic acid (410 mg, 0.945 mmol, Intermediate 16) in 2-MeTHF (10 mL) at 0° C. was treated with [(E)-4,4,4-trifluorobut-2-enyl] N-aminocarbamate (174 mg, 0.945 mmol, Intermediate 3) and isobutyl chloroformate (0.12 mL, 0.898 mmol). The reaction was stirred for 15 min, at which point a solution of NMM (0.10 mL, 0.945 mmol) in 2-MeTHF (10 mL) was added. The reaction was warmed to r.t. and stirred for 1 h. The reaction was slowly quenched with H2O (10 mL) and the aqueous layer was extracted with EtOAc (2×10 mL). The combined organic layers were washed with satd aq NaHCO3 solution (2×10 mL) and brine (10 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (90% purity, 600 mg, 0.900 mmol, 95% yield); 1H NMR (400 MHz, CDCl3) δ 9.17 (d, J=2.1 Hz, 1H), 8.57 (s, 1H), 8.51 (s, 1H), 8.02 (s, 1H), 7.75 (d, J=8.8 Hz, 1H), 7.58 (s, 1H), 7.50 (dd, J=8.7, 1.9 Hz, 1H), 7.17-6.92 (m, 1H), 6.37 (d, J=15.3 Hz, 1H), 5.93-5.78 (m, 1H), 4.95-4.81 (m, 1H), 4.77-4.62 (m, 2H), 4.34-4.22 (m, 2H), 3.51-3.38 (m, 1H), 2.22-2.11 (m, 1H), 1.99-1.80 (m, 3H), 1.49-1.27 (m, 9H); M/Z: 600, 602 [M+H]+, ESI+, RT=3.33 (S4).
A solution of tert-butyl (2R,5S)-5-[(7-chloroquinoline-3-carbonyl)amino]-2-[[[(E)-4,4,4-trifluorobut-2-enoxy]carbonylamino]carbamoyl]piperidine-1-carboxylate (90% purity, 505 mg, 0.758 mmol), TsCl (217 mg, 1.14 mmol) and K3PO4 (482 mg, 2.27 mmol) in anhydrous ACN (15 mL) was stirred at 60° C. for 4 h. The reaction was cooled to 0° C. and quenched slowly with satd aq NH4OH solution (1 mL). The solution was diluted with H2O (40 mL) and extracted with EtOAc (2×40 mL). The combined organic extracts were washed with satd aq NaHCO3 solution (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by prep. HPLC (Method 5), and the relevant fractions were neutralised with satd aq NaHCO3 solution and extracted with EtOAc (2×30 mL). The combined organic extracts were washed with brine (20 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (132 mg, 0.218 mmol, 29% yield); 1H NMR (400 MHz, CDCl3) δ 9.23 (d, J=2.1 Hz, 1H), 8.53 (d, J=1.7 Hz, 1H), 8.13 (d, J=1.7 Hz, 1H), 7.82 (d, J=8.7 Hz, 1H), 7.57 (dd, J=8.7, 2.0 Hz, 1H), 7.08-6.65 (m, 1H), 6.62-6.50 (m, 1H), 6.16-6.01 (m, 1H), 5.75-5.34 (m, 1H), 5.18-5.03 (m, 2H), 4.42-4.33 (m, 1H), 4.32-4.22 (m, 1H), 3.36-3.13 (m, 1H), 2.30-1.94 (m, 4H), 1.48 (s, 9H); M/Z: 582, 584 [M+H]+, ESI+, RT=3.81 (S4).
To a solution of tert-butyl (2R,5S)-5-[(7-chloroquinoline-3-carbonyl)amino]-2-[5-[(E)-4,4,4-trifluorobut-2-enoxy]-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate (150 mg, 0.247 mmol, Example 47) in anhydrous DCM (3 mL) was added ZnBr2 (223 mg, 0.990 mmol) and the mixture was stirred at r.t. for 3 h. Additional anhydrous DCM (3 mL) and ZnBr2 (223 mg, 0.990 mmol) were added and the mixture was stirred at r.t. for 6 h. The reaction mixture was quenched with satd aq NaHCO3 solution (10 mL) and extracted with DCM:IPA (4:1) (2×10 mL). The combined organic extracts were washed with brine (10 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by prep. HPLC (Method 5) and the relevant fractions were neutralised with satd aq NaHCO3 solution, combined and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine (10 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (17 mg, 0.0346 mmol, 14% yield) as an off-white powder; 1H NMR (400 MHz, CDCl3) δ 9.27 (d, J=2.1 Hz, 1H), 8.59 (d, J=1.9 Hz, 1H), 8.17 (s, 1H), 7.87 (d, J=8.7 Hz, 1H), 7.59 (dd, J=8.7, 2.0 Hz, 1H), 6.70 (d, J=6.7 Hz, 1H), 6.62-6.49 (m, 1H), 6.14-5.99 (m, 1H), 5.15-5.06 (m, 2H), 4.37-4.21 (m, 1H), 4.18-4.06 (m, 1H), 3.42 (dd, J=12.1, 3.1 Hz, 1H), 2.79 (dd, J=12.2, 6.7 Hz, 1H), 2.26-2.10 (m, 2H), 2.09-2.01 (m, 1H), 1.89-1.75 (m, 1H); M/Z: 482, 484 [M+H]+, ESI+, RT=3.00 (S6).
Example compound in Table 7 was synthesised according to the general route 18 as exemplified by Example 48 using the corresponding intermediates. The corresponding boc protected intermediate of the numbered example is also an example of the invention.
1H NMR Data
1H NMR (500 MHz, DMSO-d6) δ 9.29 (d, J = 2.2 Hz, 1H), 8.86 (d, J = 2.1 Hz, 1H), 8.63 (d, J = 7.7 Hz, 1H), 8.20-8.09 (m, 2H), 7.74 (dd, J = 8.7, 2.2 Hz, 1H), 4.73- 4.63 (m, 2H), 4.52-4.42 (m, 2H), 3.98-3.88 (m, 1H), 3.85-3.77 (m, 1H),
To a solution of (1s,3s)-3-(trifluoromethoxy)cyclobutane-1-carbohydrazide (237 mg, 1.20 mmol, Intermediate 5), (2R,5S)-1-tert-butoxycarbonyl-5-[(7-chloroquinoline-3-carbonyl)amino]piperidine-2-carboxylic acid (500 mg, 1.14 mmol, Intermediate 16) and DIPEA (0.60 mL, 3.42 mmol) in anhydrous DMF (10 mL) was added HATU (521 mg, 1.37 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by chromatography on silica gel (0-100% EtOAc in heptane) to afford the title compound (75% purity, 436 mg, 0.533 mmol, 47% yield) as a terracotta solid; M/Z: 614, 616 [M+H]+, ESI+, RT=0.88 (S2).
A solution of tert-butyl (2R,5S)-5-(7-chloroquinoline-3-amido)-2-{N-[(1s,3s)-3-(trifluoromethoxy)cyclobutanecarbonyl]hydrazinecarbonyl}piperidine-1-carboxylate (75% purity, 436 mg, 0.533 mmol), TsCl (305 mg, 1.60 mmol) and K2CO3 (368 mg, 2.66 mmol) in ACN (15 mL) was stirred at 65° C. overnight. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (2×20 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The residue was purified by prep. HPLC (Method 5) to afford the title compound (124 mg, 0.200 mmol, 38% yield) as a white solid; 1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J=2.0 Hz, 1H), 8.86 (s, 1H), 8.68 (d, J=6.2 Hz, 1H), 8.25-8.08 (m, 2H), 7.75 (dd, J=8.8, 2.1 Hz, 1H), 5.52 (s, 1H), 4.91 (p, J=7.4 Hz, 1H), 4.13 (d, J=25.8 Hz, 2H), 3.46 (ddd, J=17.6, 9.8, 7.8 Hz, 1H), 3.06 (d, J=11.7 Hz, 1H), 2.91-2.79 (m, 2H), 2.08 (d, J=11.7 Hz, 1H), 1.98-1.77 (m, 2H), 1.29 (s, 9H); M/Z: 596, 598 [M+H]+, ESI+, RT=1.02 (S2).
To a solution of tert-butyl (2R,5S)-5-(7-chloroquinoline-3-amido)-2-{5-[(1s,3s)-3-(trifluoromethoxy)cyclobutyl]-1,3,4-oxadiazol-2-yl}piperidine-1-carboxylate (124 mg, 0.200 mmol, Example 50) in DCM (10 mL) was added ZnBr2 (135 mg, 0.599 mmol) and the mixture was stirred at r.t. overnight. Additional ZnBr2 (135 mg, 0.599 mmol) was added and the mixture was stirred at r.t. for 3 h. The reaction mixture was concentrated in vacuo and the residue was dissolved in EtOAc. The organic layer was washed with satd aq NH4Cl solution, dried over Na2SO4, and concentrated in vacuo. The residue was purified by prep. HPLC (Method 5) to afford the title compound (49 mg, 0.0931 mmol, 47% yield) as a white solid; 1H NMR (500 MHz, DMSO-d6) δ 9.30 (d, J=2.2 Hz, 1H), 8.87 (d, J=1.8 Hz, 1H), 8.66 (d, J=7.7 Hz, 1H), 8.56-8.22 (m, 1H), 8.19-8.13 (m, 2H), 7.74 (dd, J=8.7, 2.1 Hz, 1H), 4.91 (p, J=7.5 Hz, 1H), 3.93 (ddd, J=17.7, 9.0, 3.0 Hz, 2H), 3.17 (dd, J=11.8, 3.3 Hz, 1H), 2.90-2.81 (m, 2H), 2.62-2.55 (m, 1H), 2.08 (d, J=10.4 Hz, 2H), 1.82-1.71 (m, 1H), 1.70-1.58 (m, 1H); M/Z: 496, 498 [M+H]+, ESI+, RT=2.06 (S4).
Example compound in Table 8 was synthesised according to the general route 19 as exemplified by Example 51 using the corresponding intermediates. The corresponding boc protected intermediate of the numbered example is also an example of the invention.
1H NMR Data
1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 2.1 Hz, 1H), 8.86 (d, J = 1.9 Hz, 1H), 8.63 (d, J = 7.7 Hz, 1H), 8.20-8.11 (m, 2H), 7.74 (dd, J = 8.7, 2.1 Hz, 1H), 4.91 (p, J = 7.4 Hz, 1H), 4.00- 3.88 (m, 2H), 3.50-3.40
To a solution of (2S,5R)-1-tert-butoxycarbonyl-5-[(3,4-dichlorobenzoyl)amino]piperidine-2-carboxylic acid (92% purity, 0.50 g, 1.10 mmol, Intermediate 18), 2-(trifluoromethoxy)ethyl N-aminocarbamate (207 mg, 1.10 mmol, Intermediate 4) and DIPEA (0.58 mL, 3.31 mmol) in anhydrous DMF (10 mL) was added HATU (503 mg, 1.32 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (2×30 mL). The combined organic extracts were dried over MgSO4 and concentrated in vacuo. The residue was purified by chromatography on silica gel (10-100% EtOAc in heptane) to afford the title compound (80% purity, 486 mg, 0.833 mmol, 48% yield) as a colourless oil; 1H NMR (500 MHz, CDCl3) δ 8.05-7.89 (m, 1H), 7.88-7.81 (m, 1H), 7.62-7.56 (m, 1H), 7.55-7.49 (m, 1H), 6.79-6.63 (m, 1H), 6.39-6.15 (m, 1H), 4.90-4.75 (m, 1H), 4.45-4.32 (m, 2H), 4.25-4.15 (m, 3H), 3.38-3.24 (m, 1H), 2.35-2.06 (m, 2H), 2.03-1.63 (m, 2H), 1.55-1.38 (m, 9H); M/Z: 587, 589, 591 [M+H]+, ESI+, RT=0.99 (S2).
A solution of tert-butyl (2S,5R)-5-[(3,4-dichlorobenzoyl)amino]-2-[[2-(trifluoromethoxy)ethoxycarbonylamino]carbamoyl]piperidine-1-carboxylate (80% purity, 250 mg, 0.341 mmol) and TsCl (130 mg, 0.681 mmol) in anhydrous ACN (3 mL) was stirred at r.t. for 10 min. K2CO3 (141 mg, 1.02 mmol) was added and the mixture was stirred at 80° C. for 2 h. The reaction mixture was diluted with EtOAc (15 mL) and washed with satd aq NaHCO3 solution (10 mL) and brine (10 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by chromatography on silica gel (10-100% EtOAc in heptane) to afford the title compound (71% purity, 80 mg, 0.0998 mmol, 29% yield) as a colourless oil; 1H NMR (500 MHz, CDCl3) δ 7.86-7.81 (m, 1H), 7.61-7.48 (m, 2H), 4.75-4.67 (m, 2H), 4.37-4.32 (m, 2H), 4.28-4.22 (m, 1H), 4.22-4.16 (m, 1H), 3.21 (s, 1H), 2.36-2.05 (m, 3H), 2.03-1.95 (m, 1H), 1.66-1.59 (m, 2H), 1.48 (s, 9H); M/Z: 569, 571, 573 [M+H]+, ESI+, RT=1.04 (S2).
To a solution of tert-butyl (2S,5R)-5-[(3,4-dichlorobenzoyl)amino]-2-[5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl]piperidine-1-carboxylate (71% purity, 80 mg, 0.0998 mmol, Example 53) in anhydrous DCM (2 mL) was added ZnBr2 (67 mg, 0.299 mmol) and the mixture was stirred at r.t. overnight. The reaction mixture was diluted with EtOAc (10 mL) and washed with H2O (8 mL). The organic layer was dried over MgSO4 and concentrated in vacuo. The residue was purified by prep. HPLC (Method 3) to afford the title compound (14 mg, 0.0293 mmol, 29% yield) as a white solid; 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J=2.0 Hz, 1H), 7.62 (dd, J=8.3, 2.1 Hz, 1H), 7.53 (d, J=8.3 Hz, 1H), 6.50 (d, J=5.8 Hz, 1H), 4.74-4.68 (m, 2H), 4.38-4.32 (m, 2H), 4.18 (ddt, J=11.0, 7.4, 3.8 Hz, 1H), 4.09 (dd, J=6.5, 4.2 Hz, 1H), 3.38-3.32 (m, 1H), 2.75-2.68 (m, 1H), 2.21-1.96 (m, 4H), 1.80-1.72 (m, 1H); M/Z: 469, 471, 473 [M+H]+, ESI+, RT=2.04 (S4).
A solution of isobenzofuran-1,3-dione (854 mg, 5.8 mmol) and 2-aminopropane-1,3-diol (521 mg, 5.7 mmol) in toluene (20 mL) was heated at 110° C. for 24 h. The reaction mixture was cooled to 62° C. and treated with MTBE (20 mL), resulting in precipitation of a white powder. The suspension was intermediate 4 stirred for 1 h, before being filtered hot to collect the precipitate. The precipitate was washed with warm MTBE (20 mL) and dried in vacuo to afford the title compound (786 mg, 3.45 mmol, 60% yield) as a white powder; 1H NMR (500 MHz, DMSO-d6) δ 7.87-7.81 (m, 4H), 4.89-4.84 (m, 2H), 4.27-4.20 (m, 1H), 3.83-3.76 (m, 2H), 3.69-3.62 (m, 2H); M/Z: 222 [M+H]+, ESI+, RT=0.73 (S1).
A solution of benzyloxyacetaldehyde (0.25 mL, 1.77 mmol), PTSA (28 mg, 0.15 mmol) and 2-[2-hydroxy-1-(hydroxymethyl)ethyl]isoindoline-1,3-dione (336 mg, 1.47 mmol) in toluene (30 mL) was heated at reflux under Dean-Stark conditions for 18 h. The reaction mixture was cooled to r.t. and washed sequentially with satd aq NaHCO3 solution (2×10 mL) and brine (10 mL). The organic layer was dried over Na2SO4, concentrated in vacuo, and purified by chromatography on silica gel (0-35% EtOAc in heptane) to afford the title compound (303 mg, 0.82 mmol, 55% yield) as a colourless oil; 1H NMR (400 MHz, chloroform-d) δ 7.90-7.82 (m, 2H), 7.79-7.71 (m, 2H), 7.41-7.34 (m, 4H), 7.34-7.29 (m, 1H), 4.91 (t, J=4.5 Hz, 1H), 4.74-4.66 (m, 1H), 4.64 (s, 2H), 4.52-4.43 (m, 2H), 4.09 (dd, J=10.8, 4.9 Hz, 2H), 3.60 (d, J=4.5 Hz, 2H).
A suspension of 2-[trans-2-[(benzyloxy)methyl]-1,3-dioxan-5-yl]-2,3-dihydro-1H-isoindole-1,3-dione (393 mg, 1.06 mmol) and Pd/C (10%, 112 mg, 0.11 mmol) in EtOH (10 mL) and EtOAc (6 mL) was stirred under H2 for 5 h. The reaction mixture was purged with N2, warmed to near reflux, and then filtered through a pad of Celite. The filtrate was concentrated in vacuo to afford the title compound (94% purity, 260 mg, 0.93 mmol, 88% yield) as a white solid; 1H NMR (400 MHz, chloroform-d) b 7.90-7.80 (m, 2H), 7.79-7.66 (m, 2H), 4.78 (t, J=4.3 Hz, 1H), 4.69-4.58 (m, 1H), 4.47 (dd, J=10.8 Hz, 2H), 4.07 (dd, J=10.7, 4.8 Hz, 2H), 3.68 (d, J=4.2 Hz, 2H), 1.92 (s, 1H).
TEMPO (0.13 g, 0.80 mmol) was added to a solution of 2-[trans-2-(hydroxymethyl)-1,3-dioxan-5-yl]-2,3-dihydro-1H-isoindole-1,3-dione (89% purity, 2.37 g, 8.01 mmol) in ACN (66 mL) and 0.67 M aq NaH2PO4 solution (66 mL). The reaction mixture was warmed to 35° C. A solution of NaClO2 (80%, 1.83 g, 16.0 mmol) in H2O (15 mL) was added, followed by NaOCl (5.0%, 0.5 mL, 0.41 mmol). The reaction mixture was stirred at 35° C. for 20 h. Additional TEMPO (0.13 g, 0.80 mmol), NaClO2 (80%, 1.83 g, 16.0 mmol) and NaOCl (5.0%, 0.5 mL, 0.41 mmol) were added and the reaction mixture was stirred at 35° C. for 24 h. Additional TEMPO (0.13 g, 0.80 mmol), NaClO2 (80%, 1.83 g, 16.0 mmol) and NaOCl (5.0%, 0.5 mL, 0.41 mmol) were added and the mixture was stirred at 35° C. for 24 h. The reaction mixture was concentrated in vacuo. The aqueous residue was basified to pH 9 using satd aq NaHCO3 solution, and washed with EtOAc (2×20 mL). The aqueous layer was cooled to 0° C. and acidified to pH 2 by the slow addition of 1 M aq HCl solution. The aqueous layer was re-extracted with EtOAc (3×20 mL). The combined organic extracts were washed with H2O (50 mL), dried over Na2SO4 and concentrated in vacuo to afford the title compound (2.10 g, 7.50 mmol, 94% yield) as an off-white powder; 1H NMR (400 MHz, methanol-d) δ 7.90-7.86 (m, 2H), 7.85-7.81 (m, 2H), 5.11 (s, 1H), 4.63-4.56 (m, 1H), 4.56-4.49 (m, 2H), 4.20-4.14 (m, 2H).
NMM (0.11 mL, 0.959 mmol) and isobutyl carbonochloridate (0.12 mL, 0.912 mmol) were added to a solution of 2-(trifluoromethoxy)ethyl N-aminocarbamate (90% purity, 201 mg, 0.959 mmol, Intermediate 4) in anhydrous 2-methyl-THF (11 mL) at 0° C. under N2 and stirred for 15 min. trans-5-(1,3-Dioxo-2,3-dihydro-1H-isoindol-2-yl)-1,3-dioxane-2-carboxylic acid (280 mg, 0.959 mmol) was added and the mixture was allowed to warm to r.t. After 1 h, the reaction mixture was quenched with H2O (1 mL) and partitioned between EtOAc (10 mL) and H2O (10 mL). The organic layer was separated and washed sequentially with satd aq NaHCO3 solution (10 mL) and brine (10 mL), dried over Na2SO4, and concentrated in vacuo to afford the title compound (80% purity, 280 mg, 0.501 mmol, 52% yield) as an off-white powder, which was used without further purification; 1H NMR (400 MHz, DMSO-d6) δ 10.02 (s, 1H), 9.34 (s, 1H), 7.91-7.79 (m, 4H), 5.01 (s, 1H), 4.41-4.09 (m, 9H).
To a suspension of trans-5-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-N-{[2-(trifluoromethoxy)ethoxy]carbonyl}-1,3-dioxane-2-carbohydrazide (80% purity, 325 mg, 0.581 mmol) in anhydrous ACN (14 mL) was added K2C03 (482 mg, 3.49 mmol) and TsCl (332 mg, 1.74 mmol) and stirred at 80° C. for 3 h. The reaction mixture was cooled to r.t., quenched with H2O (1 mL), and partitioned between EtOAc (10 mL) and H2O (10 mL). The layers were separated and the aqueous layer reextracted with EtOAc (10 mL). The combined organic extracts were washed with satd aq NaHCO3 solution (10 mL) and brine (10 mL), dried over Na2SO4, and concentrated in vacuo. The residue was purified by reverse phase column chromatography (Method 6) to afford the title compound (90% purity, 99 mg, 0.208 mmol, 36% yield) as a off-white powder; 1H NMR (500 MHz, chloroform-d) δ 7.91-7.85 (m, 2H), 7.85-7.75 (m, 2H), 5.85 (s, 1H), 4.88-4.79 (m, 1H), 4.79-4.73 (m, 2H), 4.65 (dd, J=11.3 Hz, 2H), 4.40-4.33 (m, 2H), 4.25 (dd, J=11.0, 4.9 Hz, 2H).
To a solution of 2-[trans-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}-1,3-dioxan-5-yl]-2,3-dihydro-1H-isoindole-1,3-dione (90% purity, 99 mg, 0.208 mmol) in EtOH (3 mL) was added NH2NH2—H2O (80% purity, 15 μL, 0.249 mmol) and the mixture was stirred at 40° C. for 48 h. The reaction was cooled to r.t. and the resultant precipitate was removed by filtration, washing with EtOH. The filtrate was concentrated in vacuo to afford the title compound (60% purity, 60 mg, 0.120 mmol, 58% yield) which was used without further purification; M/Z: 300 [M+H]+, ESI+, RT=0.70 (S1).
A solution of 7-chloroquinoline-3-carboxylic acid (25 mg, 0.120 mmol) in anhydrous 2-methyl-THF (2 mL) at 0° C. was treated with NMM (13 μL, 0.120 mmol) and isobutyl carbonochloridate (15 μL, 0.114 mmol). The mixture was stirred for 15 min before trans-2-{5-[2-(trifluoromethoxy)ethoxy]-1,3,4-oxadiazol-2-yl}-1,3-dioxan-5-amine (60% purity, 60 mg, 0.120 mmol) was added slowly and then stirred at r.t. for 1 h. The reaction mixture was cooled to 0° C., quenched with H2O (5 mL), and then extracted with EtOAc (5 mL). The combined organic extracts were washed with satd aq NaHCO3 solution (5 mL) and brine (5 mL), dried over Na2SO4, concentrated in vacuo, and purified by prep. HPLC (Method 4). The relevant fractions were concentrated in vacuo at r.t. to afford the title compound (4.0 mg, 8.10 μmol, 6.7% yield) as a white powder; 1H NMR (500 MHz, CDCl3) δ 9.32 (d, J=2.2 Hz, 1H), 8.64 (d, J=2.0 Hz, 1H), 8.21 (d, J=1.9 Hz, 1H), 7.91 (d, J=8.7 Hz, 1H), 7.63 (dd, J=8.7, 2.0 Hz, 1H), 6.79 (d, J=8.3 Hz, 1H), 5.97 (s, 1H), 4.83-4.74 (m, 2H), 4.56 (dd, J=11.8, 3.1 Hz, 2H), 4.51-4.43 (m, 1H), 4.42-4.36 (m, 2H), 4.00 (dd, J=11.9, 5.1 Hz, 2H); M/Z: 489, 491 [M+H]+, ESI+, RT=3.24 (S4).
Example compounds were tested in the HEK-ATF4 High Content Imaging assay to assess their pharmacological potency to prevent Tunicamycin induced ISR. Wild-type HEK293 cells were plated in 384-well imaging assay plates at a density of 12,000 cells per well in growth medium (containing DMEM/F12, 10% FBS, 2 mM L-Glutamine, 100 U/mL Penicillin—100 μg/mL Streptomycin) and incubated at 37° C., 5% CO2. 24 h later, the medium was changed to 50 μL assay medium per well (DMEM/F12, 0.3% FBS, 2 mM L-Glutamine, 100 U/mL Penicillin—100 μg/mL Streptomycin). Example compounds were serially diluted in DMSO, spotted into intermediate plates and prediluted with assay medium containing 3.3 μM Tunicamycin to give an 11-fold excess of final assay concentration. In addition to the example compound testing area, the plates also contained multiples of control wells for assay normalization purposes, wells containing Tunicamycin but no example compounds (High control), as well as wells containing neither example compound nor Tunicamycin (Low control). The assay was started by transferring 5 μL from the intermediate plate into the assay plates, followed by incubation for 6 h at 37° C., 5% CO2. Subsequently, cells were fixed (4% PFA in PBS, 20 min at r.t.) and submitted to indirect ATF4 immunofluorescence staining (primary antibody rabbit anti ATF4, clone D4B8, Cell Signaling Technologies; secondary antibody Alexa Fluor 488 goat anti-rabbit IgG (H+L), Thermofisher Scientific). Nuclei were stained using Hoechst dye (Thermofisher Scientific), and plates were imaged on an Opera Phenix High Content imaging platform equipped with 405 nm and 488 nm excitation. Finally, images were analyzed using script based algorithms. The main readout HEK-ATF4 monitored the ATF4 signal ratio between nucleus and cytoplasm. Tunicamycin induced an increase in the overall ATF4 ratio signal, which was prevented by ISR modulating example compounds. In addition, HEK-CellCount readout was derived from counting the number of stained nuclei corresponding to healthy cells. This readout served as an internal toxicity control. The example compounds herein did not produce significant reduction in CellCount.
HEK ATF4 Activity of the tested example compounds is provided in Table 9 as follows: +++=IC50 1-500 nM; ++=IC50>500-2000 nM; +=IC50>2000-15000 nM.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20203311.4 | Oct 2020 | EP | regional |
| 21192154.9 | Aug 2021 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/079209 | 10/21/2021 | WO |
